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ABSTRACT OF THE DISSERTATION 
The RpL13a snoRNA U33 Forms Novel snoRNPs During Lipotoxicity 
by 
Miquia Sherree Henderson 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular and Cell Biology  
Washington University in St. Louis, 2017 
Professor Jean Shaffer, Chair 
Lipid overload contributes to the pathogenesis of diabetic complications, causing tissue 
damage and cell death in a number of organ systems. This process is termed 
lipotoxicity. Animal and cell culture studies have demonstrated that oxidative stress and 
endoplasmic reticulum stress are major pathways engaged in the lipotoxic response. 
However, the molecular mechanisms of lipotoxicity are not well understood. A genetic 
screen revealed that small nucleolar RNAs (snoRNAs) encoded in the introns of the 
Rpl13a locus are critical for cell death in response to lipotoxicity.  Initial studies have 
suggested that the Rpl13a snoRNAs function in this pathway through non-canonical 
modes of action, involving trafficking to the cytoplasm. 
 
To gain insight into the mechanism of action of Rpl13a snoRNA U33, snoRNPs were 
isolated from cells. We observed many previously undescribed snoRNA-interacting 
proteins in whole cell lysates. Identification of proteins that co-precipitate from cytosolic 
and post-cytosolic lysates, under lipotoxic stress and basal conditions, demonstrated 
that U33-containing complexes are dynamic, and the composition of these complexes 
ix 
 
depends on both subcellular localization and the presence or absence of stress. We 
hypothesized that Rpl13a snoRNAs may direct modification of cytosolic mRNAs to 
affect their abundance or translation efficiency. Consistent with this model, RNA-seq 
analysis identified over 200 transcripts with significant changes in abundance under 
lipotoxic conditions. Metabolic labeling revealed that many of these changes are due, at 
least in part, to changes in transcript stability. Furthermore, ribosome footprinting 
indicated that a number of transcripts are differentially translated during lipotoxicity. 
Together, these studies add to a growing body of evidence that snoRNAs function in 
roles beyond the processing and modification of ribosomal RNAs.
 
 
1 
Chapter 1 
Introduction 
 
1.1 Lipotoxicity in Disease 
Nearly 30 million adults in the United States have diabetes, with another 87 million 
estimated to have prediabetes.1 The majority of these individuals have type 2 diabetes. 
The rise in disease prevalence in recent years is likely to be related to the alarming rise 
in rates of obesity, which is associated with hyperlipidemia and insulin resistance.2-7 
Diabetes poses an enormous burden on our health care system, with estimated annual 
medical costs of $176 billion.1 Beyond treatment of the primary metabolic abnormalities 
of diabetes, patients require care for the many complications of the disease that impact 
the eye, kidney, heart and vascular system, reproductive function, and nervous system. 
Cardiovascular disease is the most common cause of death among patients with 
diabetes,8 who have a 2.4- to 5-fold increased risk of heart failure9 and a 2-4-fold 
increased risk of atherosclerosis.10 Further, diseases of the cardiovascular system are 
more aggressive in diabetics, who have an increased risk of morbidity and mortality 
following myocardial infarction.11,12 
 
Patients with type 2 diabetes frequently have elevated fasting serum triglycerides13 and 
elevated post-prandial serum triglycerides,14 in addition to alterations in lipoprotein 
levels and serum glucose abnormalities, which contribute to many disease 
complications.  When triglycerides and free fatty acids (FFAs) exceed adipose tissue 
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storage capacity, or when lipolysis in adipose tissues is dysregulated, such as occurs in 
insulin resistance, the excess lipid presented to non-adipose tissues results in uptake in 
excess of the capacity of these tissues to metabolize the lipid.15-18 Patients with type 2 
diabetes have evidence for increased triglyceride accumulation in the heart, skeletal 
muscle, liver, and pancreas.19-22 
 
Accumulation of excess lipid is associated with organ dysfunction. Roger Unger coined 
the term “lipotoxicity” to describe the untoward consequences of ectopic lipid 
accumulation.23 In his studies of the Zucker diabetic fatty rat (ZDF), pancreata of obese 
animals had decreased glucose-stimulated insulin secretion.24 The ZDF rats showed 
significant amounts of myocardial triglyceride relative to lean controls and had 
significant cardiac dysfunction, as indicated by increased end diastolic left ventricular 
diameter and decreased fractional shortening measured by echocardiogram.25 Lipid-
induced cardiac dysfunction has also been studied in a number of transgenic mouse 
models in which overexpression of lipid transport proteins in cardiac myocytes drives 
excessive lipid uptake despite normal serum lipid levels.26-28 In human subjects, excess 
lipid accumulation in the heart is also associated with cardiac dysfunction.29 
Furthermore, exposure of skeletal muscle to excess lipid is associated with insulin 
resistance in human subjects.30,31 Collectively, these studies suggest an important role 
for lipid overload in the pathogenesis of diabetes and its complications. 
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1.2  Molecular Mechanisms of Lipotoxicity 
Initial understanding of the molecular mechanisms that underlie lipotoxicity has come 
from cell culture studies in which the media is supplemented with 500µM – 1mM 
saturated fatty acid (e.g. palmitate) complexed to albumin for 24-72 hours to model 
pathophysiological lipid excess. Saturated long chain fatty acids are not efficiently 
incorporated into triglyceride pools, but rather are rapidly incorporated into 
phospholipids, leading to significantly increased saturation of membrane lipids in the 
endoplasmic reticulum and diminished cardiolipin content of mitochondria.32,33 
Ultrastructural studies have revealed significant changes in the ER morphology of 
palmitate treated cells, resulting in marked distention of the rough ER in Chinese 
hamster ovary (CHO) cells and aggregation plus abnormal distribution of the ER in INS-
1 immortalized pancreatic beta cells.32,34 Lipotoxicity alters ER integrity, as evidenced 
by release of calcium from the ER and the detection of luminal proteins GRP78 and PDI 
in the cytosolic fraction of CHO cells following palmitate treatment.32 Furthermore, 
saturated lipid overload induces ER stress, as evidenced by the increased splicing of 
XBP-1, phosphorylation of PERK, and induction of the transcription factor CHOP.34   
 
Palmitate treatment also results in significant accumulation of reactive oxygen species 
(ROS).35,36 Lipotoxic stress induces free radical production in cultured aortic smooth 
muscle cells as measured by electronic spin resonance.37 Inhibition of this ROS 
production by an NADPH oxidase inhibitor suggests that superoxide may be an 
important species of free radical in this system. Palmitate treatment of cultured Chinese 
hamster ovary cells leads to increased ROS as detected by dichlorodihydrofluorescein 
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diacetate that can be attenuated with dihydroxy-1,3-benzene-disulfonic acid (DBDA) or 
pyrrolidine dithiocarbamate (PDTC), agents known to have antioxidant effects.35 Co-
treatment of cells with DBDA or PDTC during lipotoxicity blocks induction of caspase 3 
activity and DNA laddering, indicating a causative role for oxidative stress in the 
apoptotic response to lipotoxicity.35 However, the antioxidant tocopheral did not 
abrogate changes in ER morphology with palmitate treatment, even though the amount 
of ROS was significantly inhibited, indicating that some lipotoxic effects on the ER are 
independent of ROS.32  
 
While treatment with saturated long-chain fatty acids has been shown to have 
deleterious effects, treatment with unsaturated long-chain fatty acids (e.g. oleate) is 
protective. Oleate does not induce ROS, alterations in ER morphology or membrane 
integrity, or apoptosis.32,35,38,39 Remarkably, while exposure to saturated fatty acids 
results in the death of cultured neonatal cardiomyocytes and rat b-cells, co-treatment 
with equimolar amounts of unsaturated fatty acids rescues the cells from apoptosis.35,36 
The observations that excessive saturated fatty acids are particularly toxic suggests that 
saturated and unsaturated fatty acids may turn on different molecular pathways when 
they are present in excess. 
 
In order to further elucidate the molecular mechanism of lipotoxicity, the Schaffer lab 
performed a genetic screen to identify critical mediators of lipotoxicity in CHO cells. 
CHO cells are fibroblasts that are sensitive to palmitate-induced cell death and well-
suited to genetic screens because they are genetically diploid.40,41 CHO cells were 
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transduced with a ROSAbgeo retroviral promoter trap at a low multiplicity of infection to 
obtain an average of less than 1 insertion event per ten cells.36 The integrated provirus 
contains a neomycin resistance cassette, but lacks its own promoter. Thus, the 
antibiotic resistance gene encoded within the provirus will not be expressed unless the 
integration occurs in close proximity to an actively transcribed RNA polymerase II 
promoter. Following selection with neomycin for 48 hours, only mutant cells in which a 
promoter is trapped, and hence a gene is disrupted, should survive. Mutants were then 
selected by growth in media containing 500 µM palmitate for 48 hours. This treatment is 
lethal to wild type cells, and mutants that survived were likely to contain an insertion in a 
gene critical to the lipotoxic response. 5’-RACE was used to identify the disrupted 
genes, and genetic validation experiments were performed to confirm the roles of the 
disrupted genes in lipotoxicity.36,42,43 
 
1.3  Identification of snoRNAs as mediators of 
lipotoxicity 
The Rpl13a gene was identified as the insertion site in the 6F2 mutant, which was 
resistant to palmitate-induced cell death but not general inducers of cell death.42 This 
locus encodes the RPL13a protein, a component of the large ribosomal subunit, and 
four intronic C/D box small nucleolar RNAs (snoRNAs), U32a, U33, U34, and U35a. 
Although the mutant cells were complemented with the genomic Rpl13a sequence, 
restoring palmitate sensitivity, the cDNA sequence did not complement the mutant. 
Furthermore, knockdown of the mRNA in wild type cells did not confer palmitate 
resistance, whereas knockdown of at least three of the Rpl13a snoRNAs in wild type 
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cells resulted in palmitate resistance. These findings indicate that the Rpl13a snoRNAs 
are critical mediators of lipotoxicity. This was the first study to suggest a role for 
snoRNAs in the response to metabolic stress.   
 
1.4 Small Nucleolar RNAs 
SnoRNAs are non-coding RNAs, typically 70 to 150 nucleotides in length, named for 
their primary location in the nucleolus. Two main classes of snoRNAs have been 
described – H/ACA box and C/D box – which are distinguished based on conserved 
sequence elements. H/ACA snoRNAs contain two hairpin structures separated by a 
single-stranded hinge region containing the H box motif (consensus sequence 
ANANNA).44 The ACA box motif is located three nucleotides from the 3’-end of the 
RNA.45 C/D box snoRNAs contain a single k-turn motif that separates the conserved C 
box (UGAUGA) and D box (CUGA) sequence elements.46 Most metazoan snoRNAs are 
intron-encoded, often in housekeeping genes.47-50 A small number are independently 
transcribed by RNA polymerase II and subsequently modified with a trimethylguanosine 
cap at the 5’ end.46,51 Intronic snoRNAs are processed from pre-mRNAs, predominantly 
by exonucleolytic trimming of excised, debranched introns.52,53 C/D box snoRNAs are 
found 70-80 nucleotides upstream of the 3’ splice site, a location that is critical for 
efficient snoRNA production.54 On the other hand, location of intronic H/ACA snoRNAs 
relative to the 3’ splice site is more permissive.55 For both snoRNA classes, the 
conserved sequence elements in their respective boxes are required for metabolic 
stability and proper snoRNA processing.56-59  
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snoRNAs interact with a number of proteins transiently. The proteins Naf1p and Shq1p 
are assembly factors that mimic molecules that H/ACA snoRNAs will later associate 
with (proteins and RNA) to prevent nonspecific interactions.60,61 H/ACA snoRNP 
assembly occurs during or shortly after transcription, and is an independent molecular 
event from splicing of the host transcript.55,62 The proteins BCD1, Pih1/Nop17, Taf9, 
Nufip, Rvb1/Tip49, and Rvb2/Tip48 associate with C/D box snoRNA precursors and are 
believed to play a role in snoRNP assembly.63,64 Nufip and hsp90 both act as scaffolds 
or chaperones to promote interactions between snoRNAs and other assembly 
factors.65,66 The R2TP complex, composed of Rvb1, Rvb2, Tah1, and Pih1, is required 
for the final assembly of the mature C/D snoRNP complex.65  
 
Each snoRNA class ultimately forms a canonical mature/core snoRNP complex 
containing four unique proteins. H/ACA snoRNAs associate with the core proteins 
Nhp2, Nop10, Gar1, and dyskerin.67-69 Core C/D box snoRNPs contain the proteins 
15.5K, Nop56, Nop58, and fibrillarin.46,47,70,71 Protein 15.5K is the first core snoRNP 
component to bind the RNA and initially associates during splicing; this binding is 
required for accumulation of the remaining snoRNP proteins.72 Recent findings indicate 
that Nop58 also binds the snoRNA early in snoRNP biogenesis, recruiting the R2TP 
complex and allowing association of the remaining core proteins.73 Nop58 and 15.5K 
are required for normal C/D box snoRNA accumulation, while all four core C/D box 
snoRNP subunits are required for localization within the nucleolus.71,74,75 
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Although snoRNAs predominantly reside in the nucleolus, transcription and assembly 
occur outside of this subnuclear compartment. Mammalian snoRNAs are primarily 
transcribed as part of a longer pre-mRNA by RNA polymerase II in the nucleoplasm, 
and snoRNA precursors are excluded from the nucleolus.76 snoRNP assembly may 
begin in nucleoplasmic splicing speckles, as 15.5K binding to C/D box snoRNAs is 
splicing-dependent and occurs before release of the intron lariat from the pre-mRNA; 
furthermore, 15.5K has been shown to transiently localize to splicing speckles before 
entering the nucleolus.72,77 C/D box snoRNAs transit through Cajal bodies, where they 
likely interact with Nopp140 and undergo final processing steps.74 Although endogenous 
H/ACA snoRNAs have not been detected in Cajal bodies, overexpressed U64 can be 
detected in Cajal bodies, raising the possibility that H/ACA snoRNAs rapidly transit this 
region en route to the nucleolus.78  
 
Each snoRNA contains an antisense element that acts as a molecular zipcode, guiding 
the entire snoRNP to a specific location on its target RNA by classical Watson-Crick 
base pairing. Most characterized snoRNAs direct chemical modification of rRNA targets, 
while a small number (including U3, U14, U8, and U17) act as molecular chaperones to 
direct ribosomal RNA (rRNA) folding or cleavage events.79-82 Whereas H/ACA snoRNAs 
direct pseudouridylation of their targets, catalyzed by the pseudouridine synthase 
dyskerin,83 box C/D snoRNAs direct 2’-O-methylation. The antisense elements of C/D 
box snoRNAs that base pair with their targets range from 10-21 nucleotides in length 
and are located immediately upstream of the D (or D’) box motif.84 Most C/D box 
snoRNAs direct the methyltransferase fibrillarin to perform 2’-O-methylation of the target 
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at the nucleotide bound five nucleotides upstream of the D box.84,85 Genetic 
manipulation of the U20 antisense element sequence demonstrated that base-pairing 
mismatches with the rRNA target were poorly tolerated, in some cases abolishing 
methylation.86 Although no single rRNA chemical modification is required, complete 
loss-of-function by knockout of fibrillarin causes collective loss of all 2’-O-methylations 
and is lethal.87,88  
 
An additional category of noncoding RNAs that localize to Cajal bodies in mature RNPs 
has been identified, termed scaRNAs. These RNAs contain one or two C/D box or 
H/ACA motifs, with most containing one of each.89 H/ACA scaRNAs contain an 
additional sequence motif, the CAB box (consensus sequence ugAG), which is required 
for Cajal body localization.78 C/D box scaRNAs also contain a Cajal body localization 
motif, termed the GU/UG wobble stem and made up of dinucleotide repeats in the 
terminal stem-loop of the apical hairpin.90 scaRNAs form RNPs with the canonical 
snoRNP core subunits and direct chemical modification of the spliceosomal small 
nuclear RNAs (snRNAs).89,91 
 
1.5  Non-canonical Functions of snoRNAs and 
implications for lipotoxicity 
Mammalian cells contain over 300 known snoRNAs. While many snoRNAs have known 
2’-O-methylation or pseudouridylation targets or have been shown to participate in 
rRNA processing, many others are considered “orphans” with no known target or 
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function. The C/D box snoRNA HBII-52 was recently shown to lack complementarity to 
rRNA and snRNA. Instead, its 18-nucleotide-long antisense element is complementary 
to the serotonin receptor 2C pre-mRNA.92 The mouse homolog, MBII-52, is essential for 
correct alternative splicing of this pre-mRNA and can form complexes with the proteins 
nucleolin and ELAVL1.93,94 Further, MBII-52 localizes to both the nucleolus and the 
nucleoplasm, while canonical snoRNAs are only found in the nucleolus.94 While MBII-52 
is thought to directly impact alternative splicing, the scaRNAs may indirectly influence 
alternative splicing by directing the chemical modification of the spliceosomal snRNAs. 
A small percentage of human ACA45 is processed into a microRNA that targets the 
3’UTR of Cdc2l6 mRNA, while Giardia lamblia miR2 is derived from a C/D box snoRNA 
and modulates translation of a reporter with miR2 target sites in the 3’-UTR.95,96 These 
studies indicate that snoRNAs can perform many unanticipated functions, and perhaps 
additional roles have yet to be identified. 
 
While the snoRNAs encoded within the Rpl13a locus are known to have rRNA targets, 
previous work in the Schaffer lab suggests that the Rpl13a box C/D snoRNAs also 
function non-canonically.42 Although each of the snoRNAs has an antisense element 
with complementarity to rRNA, primer extension analysis has shown that the ribosomal 
targets are not differentially modified in the haploinsufficient 6F2 mutant. Furthermore, 
these rRNA targets are not differentially modified in wild type or 6F2 mutant cells under 
lipotoxic conditions.42 In situ hybridization showed significant accumulation of the 
Rpl13a snoRNAs in the cytosol following palmitate treatment.42 RTqPCR performed on 
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subcellular fractions showed a similar result.97,98 Collectively, these studies suggest that 
the Rpl13a snoRNAs are likely to play a non-canonical role in lipotoxicity. 
 
Although mature snoRNPs have canonically been thought to reside in the nucleolus, 
there is much evidence that snoRNAs may have a role outside the nucleus. In addition 
to the above studies indicating that snoRNAs can be processed to miRNAs, Baserga et 
al. found that cells possess a distinct mechanism for nuclear import of snoRNAs from 
the cytoplasm,99 suggesting that snoRNAs may shuttle between the two compartments. 
Serum starvation caused the U3 snoRNP to accumulate in the cytoplasm,100 consistent 
with regulation of snoRNA function by changes in localization and thus proximity to its 
target. U8 associates with the mRNA export protein PHAX and the snRNA import 
protein Snuportin.101 Additionally, recent results have indicated that a large number of 
snoRNAs accumulate in the cytosol in response to doxorubicin, a chemotherapeutic that 
induces oxidative stress.102  
 
Localization of snoRNAs in the cytoplasm suggests that non-canonical targets may 
include mRNAs. Two early studies provided support for the notion that chemical 
modification of mRNAs may be directed by snoRNAs.  An engineered H/ACA snoRNA 
was able to direct pseudouridylation of a reporter construct, disrupting a premature 
termination codon and inducing the activity of the reporter protein.103 Similar results 
were found when C/D box snoRNA U20 was modified to direct 2’-O-methylation of an 
exogenous RNA polymerase II-transcribed target; this resulted in differential digestion of 
the target by RNase T1, indicative of an increase in methylation when the RNAs were 
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co-expressed.86  More recently, evidence for snoRNA-directed modifications of 
endogenous RNAs has come from “pseudouridine-seq” approaches. These studies 
have shown that human and yeast mRNAs contain pseudouridines that are dependent 
on the activity of dyskerin or its yeast homolog, Cbf5p.104-106  These studies support the 
notion that snoRNAs may have non-canonical functions in the modification of mRNAs. 
 
1.6  Concluding Remarks 
Hyperlipidemia is a hallmark of obesity and type 2 diabetes mellitus. Increased 
circulating lipids result in increased lipid uptake by non-adipose tissues, in which these 
lipids have damaging effects. Genetic studies have demonstrated that the Rpl13a 
snoRNAs are critical mediators of lipotoxicity, likely by a non-canonical mechanism. We 
hypothesized that identification of the RNP components of these snoRNAs would 
provide insights into their molecular role in lipotoxicity. Our studies demonstrate that 
U33 interacts with previously undescribed proteins. These interactions are dynamic and 
depend on subcellular localization and the presence/absence of metabolic stress. 
Accumulation of snoRNPs in the cytoplasm places the snoRNAs in a compartment in 
which abundant mRNAs may serve as targets. Therefore, we further hypothesized that 
the Rpl13a snoRNAs accumulate in the cytosol during lipotoxicity to direct modification 
of mRNAs, leading to changes in mRNA abundance and/or translation efficiency. Using 
RNAseq analysis and ribosome footprinting, we found changes in both mRNA 
abundance and translation efficiency of some transcripts under lipotoxic conditions. 
Together, these experiments provide new insights into the molecular events of 
lipotoxicity. 
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Chapter 2 
U33-associated Proteins 
 
2.1 Introduction 
Box C/D snoRNAs are known to form a core snoRNP with the proteins fibrillarin, Nop56, 
Nop58, and 15.5K. Other proteins have been shown to interact with C/D box snoRNAs, 
but these proteins are not considered part of the core snoRNP.  Several proteins, 
including phosphorylated adapter RNA export protein (PHAX), Nopp140, TIP48, TIP49, 
BCD1, and survival of motor neurons (SMN), have been implicated in snoRNP 
biogenesis.64,76,107-110 The non-canonical C/D box snoRNA MBII-52 was reported to 
associate with 17 proteins, many of which had not previously been described as 
snoRNP components and which may be involved in the alternative splicing of the 
serotonin receptor 2C transcript.94 In this chapter, we report a method for identification 
of U33-interacting proteins from subcellular compartments of palmitate-treated cells. We 
validated interactions between U33 and each of four proteins in the cytosol during 
lipotoxicity. These results indicate that U33 interacts with previously undescribed 
proteins, some of which may have roles in the non-canonical function of U33 in the 
cytosol. 
 
2.2 Results 
In order to isolate endogenous U33 snoRNPs using an antisense oligo, we first 
identified regions of U33 that are available for binding under conditions that preserve 
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interactions between snoRNAs and associated proteins in the snoRNP. In an approach 
analogous to that used to identify available regions of snoRNAs U8 and U13,111 RNase 
H digests were performed in the presence of antisense oligos directed against U33. 
Complementary oligos were designed against six regions tiled along the length of U33 
(Fig. 2.1A). Following sonication of cells in a mild buffer containing physiological 
concentrations of NaCl and 0.05% of the non-ionic detergent NP-40, aliquots of cell 
sonicate were incubated with RNase H and a single oligo.  Reactions containing no 
oligo served as negative controls. RNA was extracted with phenol:chloroform and 
quantified by RTqPCR using a stem-loop primer for reverse transcription that was 
complementary to the extreme 3’ end of the snoRNA and a forward PCR primer 
complementary to the extreme 5’ end of the snoRNA.42,112 With this strategy, RTqPCR 
detects intact U33, but any digestion along the length of the snoRNA precludes 
detection.  
 
Oligos tiled along the length of U33 resulted in different degrees of preservation of the 
full length U33. Following digestion in the presence of oligos 2, 5, or 6, more than 50% 
of U33 was degraded (Fig. 2.1B). However, U33 remained intact after digestion in the 
presence of oligos 1, 3, or 4 as compared to when no oligo was present. This result 
suggested that the regions complementary to oligos 2, 5, and 6 are available for binding 
to an antisense oligo. By contrast oligos 1, 3, and 4 are likely complementary to regions 
inaccessible due to secondary structure of the RNA and/or interactions between the 
RNA and proteins in the snoRNP. Therefore, an antisense oligo (ASO) complimentary 
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to U33 nucleotides 54-73, with biotin moieties at the 5’- and 3’-ends, was designed to 
isolate endogenous U33 snoRNPs.  
 
The schematic in Figure 2.2A depicts the ASO-mediated pull-down method to isolate 
U33 snoRNPs from whole cell sonicates. Following sonication of cells, biotinylated oligo 
was incubated with the sonicate to allow duplex formation with U33. Oligo-U33 snoRNP 
complexes were then captured with high capacity streptavidin beads. Pull-downs were 
performed in parallel with a sense oligo from the same region of U33, which served as a 
negative control.  
 
Pull-downs were analyzed for both RNA and protein recovery, comparing specific 
recovery with the ASO to non-specific background with the sense oligo. RTqPCR 
analysis of recovered RNA showed that U33 was enriched by over 150-fold by ASO 
pull-down in comparison to sense oligo pull-down (Fig. 2.2B). On the other hand, 
neither C/D box snoRNA U20 nor H/ACA box snoRNA U17b was significantly enriched 
by U33 ASO pull-down. Western blot of co-precipitating protein confirmed that canonical 
C/D box snoRNP core proteins Nop58 and fibrillarin were recovered in pull-downs using 
ASO but not in sense oligo pull-downs, as would be expected for U33 snoRNP proteins 
(Fig. 2.2C). These findings indicate that U33 ASO pull-down specifically isolated the 
U33 snoRNA without disrupting association of two expected snoRNP proteins.  
While pull-down followed by western blot confirmed association of U33 with canonical 
C/D box snoRNP proteins, the role of the Rpl13a snoRNAs in lipotoxicity suggests that 
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U33 might also interact with noncanonical proteins. In order to determine whether ASO-
mediated pull-down of U33 captured additional proteins besides the four canonical core 
snoRNP proteins, pull-down of U33 from whole cell sonicates was repeated. Rather 
than probe for specific proteins by western blot, co-precipitating proteins were 
separated by gel electrophoresis and visualized with the fluorescent stain SYPRO Ruby 
(Fig. 2.3A). The ASO pull-down lane contained many additional bands that were not 
present in the sense pull-down lane, and many bands present in both lanes were 
considerably more intense in the ASO lane. This result suggested that U33 might 
associate with proteins not previously described as snoRNP components. Bands that 
appeared similar in both ASO and sense pull-downs are likely to include proteins that 
are non-specifically recovered with this approach. 
 
Protein from ASO and sense pull-downs was in-solution digested, and peptides were 
analyzed by liquid chromatography/mass spectrometry (LC/MS). Proteins with a 
minimum of 2 peptides in the ASO pull-down and a 2:1 ratio of peptides detected in 
ASO versus sense pull-down in two independent replicates were considered enriched 
by the U33 ASO oligo (Table 2.1). While the canonical core C/D box snoRNP proteins 
fibrillarin and Nop58 were found to associate with U33, we did not detect Nop56 or 
15.5K, suggesting they may be less tightly associated with U33 under our experimental 
conditions. An additional 39 proteins were also identified. Although 11 of these proteins 
had been previously shown to interact with at least one snoRNA in prior 
studies,93,94,113,114 28 proteins were novel snoRNP components. In order to validate the 
mass spectrometry results, one of the most abundant proteins in the ASO pull-down, 
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heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), was directly interrogated for 
interaction with U33 by pull-down followed by western blot. Under the same conditions 
for pull-downs from whole cell sonicate as described above, immunologically-detectable 
hnRNP A1 co-precipitated with U33 ASO, while none was observed with the sense pull-
down (Fig. 2.3B). Together, these results are consistent with our hypothesis that U33 
interacts with non-canonical proteins. 
 
Since the Rpl13a snoRNAs accumulate in the cytosol of multiple cell types during 
lipotoxicity,42,97,102 we hypothesized that U33 might interact with a unique complement of 
proteins in the cytosol following treatment of cells with pathophysiological 
concentrations of palmitate, compared to nuclear U33 under homeostatic conditions. As 
shown in Figure 2.4A, treatment of NIH-3T3 cells with 500 µM palmitate for 12 hours 
results in a similar accumulation of the Rpl13a snoRNAs as has been previously shown 
for CHO cells and C2C12 myoblasts. Based on this observation, we chose NIH-3T3 
cells for the next series of experiments to compare the U33 snoRNP-proteome under 
different conditions. 
 
We next developed a method for recovering compartment-specific snoRNPs from the 
cytosol (cyto) and the remainder of the cell (post-cytosolic, post-cyto).  Buffers typically 
used for extraction of cytosolic lysates contain 100 µg/mL digitonin, but these conditions 
did not support enrichment of U33 by ASO pull-down (data not shown). In an alternate 
approach, we homogenized cells in the 0.05% NP-40 buffer used above for isolating 
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snoRNPs from whole cell sonicates, since this buffer permits binding of the ASO to U33, 
yields U33 enrichment, and preserves interactions between the snoRNA and known 
protein binding partners. Following Dounce homogenization, cytosol was separated 
from membrane-bound organelles by centrifugation and the latter were then lysed by 
sonication (post-cytosol). Western blot analysis showed the cytosolic fraction was 
enriched for the cytosolic marker hsp90 and relatively depleted of nuclear markers 
nucleophosmin and histone H3, whereas the post-cytosolic fraction was relatively 
depleted for hsp90 and enriched for the nuclear markers (Fig. 2.4B). Further, RT-qPCR 
for the predominantly nuclear RNA U6 indicated that this marker segregated between 
the cytosolic and post-cytosolic fractions as expected. Neither the protein nor RNA 
markers showed significant change with palmitate treatment. Therefore, lysates 
generated by this approach were used to investigate the proteins bound to U33 in each 
compartment. 
 
Proteins isolated from oligo-mediated pull-downs performed with cytosolic and post-
cytosolic lysates, following treatment with palmitate or vehicle, were analyzed by mass 
spectrometry. As a control, RNA isolated from these pull-downs was quantified by 
RTqPCR (Fig. 2.4D). As we had observed with whole cell sonicates, in both the 
cytosolic and post-cytosolic compartments under control and palmitate-treated 
conditions, U33 was enriched by ASO pull-down when compared to sense pull-down, 
while U20 and U17b were not. Pull-down was more efficient in the post-cytosolic 
compartment, likely reflecting the higher absolute abundance of snoRNA in the nucleus 
under both basal and stress conditions. Visualization of co-precipitating proteins by 
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SDS-PAGE and SYPRO Ruby staining again revealed many ASO-specific bands (Fig. 
2.4E). Additionally, the complement of proteins co-precipitating with cytosolic U33 
appeared different than with post-cytosolic U33. Based on the results of these controls, 
this approach specifically enriches for U33 snoRNPs and recovers substantially more 
proteins than the four canonical snoRNP proteins in both fractions under the different 
conditions. 
 
Peptides from pull-downs performed in parallel to those shown in Figure 2.4E were 
identified by mass spectrometry. Proteins with a minimum of five peptides and a 2:1 
ratio of peptides in ASO versus sense pull-down from the same fraction/condition were 
considered enriched. Given the accumulation of U33 and the other Rpl13a snoRNAs in 
the cytosol during lipotoxicity, we hypothesized that proteins uniquely associated with 
U33 in the cytosol following palmitate treatment, but not associated with U33 in the 
post-cytosol under basal conditions, might be important to the function of U33 in the 
cytosol during metabolic stress. 27 proteins were specifically associated with U33 in the 
cytosol of palmitate-treated cells, but not with U33 in the post-cytosol of vehicle-treated 
cells (Table 2.2 and Fig. 2.4F). On the other hand, proteins that only associated with 
U33 in the post-cytosol under basal conditions might be involved in tethering the 
snoRNA in the nucleus. 16 proteins were specifically associated with U33 in the nucleus 
under basal conditions but not in the cytosol during lipotoxicity (Table 2.3). Lastly, 
proteins that associated with U33 in both the cytosol during lipotoxicity and the post-
cytosol might be involved in trafficking of the snoRNA between the two compartments. 
24 proteins were enriched for association with U33 in both the cytosol following 
 
 
20 
palmitate treatment and in the post-cytosol following vehicle treatment (Table 2.4). The 
mass spectrometry results indicated that U33 interacts with many proteins that had not 
previously been described as snoRNP components, and that many of these interactions 
are compartment- and treatment-specific. 
 
Interactions between U33 and each of four proteins found to uniquely associate with the 
snoRNA in the cytosol during lipotoxicity were first validated by pull-down/western blot. 
Given that snoRNAs direct the modification of other RNAs, we hypothesized that U33 
might act in the cytosol to direct mRNA modulating proteins to specific targets. We 
therefore focused on proteins known to modulate the functions of mRNAs. Two proteins 
with highly abundant peptides in the cytosolic pull-downs under lipotoxic conditions 
were far upstream element binding protein 2 (KHSRP) and heteronuclear 
ribonucleoprotein U (hnRNP U). These proteins play a role in regulation of mRNA 
abundance through AU-rich elements (AREs).115,116 Pull-down of U33 from cytosolic 
lysates of palmitate-treated cells not only enriched for U33 in ASO pull-downs, but also 
for immunologically-detectable hnRNP U and KHSRP (Fig. 2.5A). We hypothesize that 
the U33 snoRNP may direct these proteins to AU-rich element-containing transcripts in 
order to regulate their abundance, a possibility that will be further addressed in Chapter 
3. Another pair of proteins selected for validation, Ras GTPase-activating protein-
binding protein 1 (G3bp1) and Caprin-1, are known stress granule components that 
could function in concert with U33 to directed specific transcripts to stress 
granules.117,118 U33 pull-down from cytosolic lysates followed by western blotting 
indicated co-precipitation of each protein with ASO, but not sense, pull-down (Fig. 
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2.5B). While it is possible that U33 guides these proteins to sequester specific 
transcripts for translational silencing, we did not observe induction of stress granule 
formation under the lipotoxic conditions used for generation of cytosolic and post-
cytosolic lysates (data not shown). 
 
In a complementary approach to validate snoRNA-protein interactions, identified 
proteins were immunoprecipitated from cytosolic lysates of palmitate- and vehicle-
treated cells, with a parallel immunoprecipitation with normal IgG as a negative control. 
Each of the four proteins above was precipitated by its antibody, but not by normal IgG 
(Fig. 2.6). Co-precipitating U33 and tRNA-glutamate were quantified by RTqPCR and 
enrichment was calculated as a single 2DCT. U33 was more than 2-fold enriched with 
each protein in the cytoplasm, while another small RNA, tRNA-glutamate, was not. 
Furthermore, association of U33 with cytosolic hnRNP U more than doubled during 
lipotoxic stress (Fig. 2.6A), and the amount of immunologically detectable hnRNP U in 
the cytosol increased considerably with palmitate treatment (Fig. 2.7). Similar 
enrichment in the cytosolic fractions under lipotoxic conditions was not observed for the 
other three proteins. Taken together, our validation experiments confirmed interactions 
of U33 with hnRNP U, KHSRP, Caprin-1, and G3bp1 in the cytosol of palmitate-treated 
cells. 
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2.3 Concluding Remarks and Future Directions 
We have developed a method for isolation of U33 and its protein binding partners from 
the subcellular compartments of palmitate-treated cells. Consistent with recent reports 
for another box C/D snoRNA, MBII-52,93,94 U33 was found to associate with many more 
proteins than the canonical four box C/D proteins, fibrillarin, Nop56, Nop58, and 15.5K. 
A number of these U33-associated proteins have not been previously described as 
snoRNP components.  
 
To our knowledge, this is the first description of compartment- or treatment-specific 
interactions between a snoRNA and its protein partners. While a number of U33-
associated proteins are present regardless of cell treatment or fraction, proteins that 
associate only in the lipotoxic cytosol or the post-cytosolic compartment under 
homeostatic conditions suggest that the snoRNPs are dynamic and undergo 
remodeling. We hypothesize that proteins exclusively associated with U33 in the post-
cytosolic fraction under homeostatic conditions could play a role in canonical functions 
of U33 in the nucleolus or tethering of the snoRNA in that compartment. Proteins that 
are exclusively associated with U33 in the cytosol under lipotoxic conditions may 
function in export of the snoRNA to the cyotosol or contribute to the function of the 
snoRNA outside the nucleus. 
 
We validated interactions of U33 with four specific proteins in the cytosol under lipotoxic 
conditions. Interactions with the stress-granule associated proteins, Caprin-1 and 
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G3bp1, and with the AU-rich element regulatory proteins KHSRP and hnRNP U, 
suggest that U33 may modulate the functionality of mRNAs by directing one or more of 
these proteins to mRNA targets in a sequence-specific manner. To date, there is no 
data linking lipotoxic responses to regulation of transcript abundance through AREs. As 
described in Chapter 3, AREs may be linked to the abundance of some genes 
differentially expressed during lipotoxicity. Future studies will be required to test this 
hypothesis. Proteins identified by mass spectrometry to bind U33 only in the basal post-
cytosol or in both the basal post-cytosol and lipotoxic cytosol will also be the subject of 
future studies in the Schaffer lab.  
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Figure 2.1: RNAse H defines accessible regions of U33 in snoRNP 
A. U33 sequence is shown with annotation of probes for RNase H analysis.  
B. Following incubation of cell sonicates with indicated U33 probes, RNase H digestion was 
performed to degrade RNA duplexes. Remaining U33 was quantified by RTqPCR relative to 
Rplp0. N= 3 independent experiments, graph reports mean + standard error (SE). *p<0.01 
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Figure 2.2: Development of method to isolate U33 snoRNP 
A. Scheme for isolation of endogenous U33 snoRNP using biotinylated antisense oligo. NIH-
3T3 cells were lysed by sonication in buffer containing 0.05% NP-40. Lysate was incubated for 
1.5h with a biotinylated antisense oligo complementary to U33 nucleotides 53-72. Oligo-
snoRNP complexes were captured with streptavidin-agarose, and RNA and protein were 
isolated from beads. Parallel pull-down with biotinylated sense oligo was used as negative 
control.  
B. Recovered snoRNAs were quantified by RTqPCR. Graph reports ratios of snoRNAs 
recovered with antisense (ASO) relative to sense oligos.  
C. Co-precipitating fibrillarin and Nop58 were analyzed by western blot for sense (S) and 
antisense (A) oligo pull-downs. 
For all data, n = 3 independent experiments, graphs report means + standard error (SE), and 
representative gels are shown. *, p < 0.05 
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Figure 2.3: U33 binds many proteins in whole cell sonicate 
Endogenous U33 snoRNP was isolated from whole cell sonicates of NIH-3T3 cells using 
antisense oligo (A, ASO) and parallel reaction with sense oligo (S, sense) as negative control. 
For each experiment, recovered RNA was analyzed by RTqPCR for snoRNAs. Graphs on left 
report ratio of snoRNA recovered with ASO relative to sense control. 
A. Proteins isolated from sense and antisense oligo pull-downs were separated by 
polyacrylamide gel electrophoresis and visualized after SYPRO Ruby staining.  
B. Proteins isolated from sense and antisense oligo pull-downs were analyzed by western 
blotting for fibrillarin and hnRNP A1.  
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Table 2.1 U33-associated proteins in whole cell sonicate 
NIH-3T3 cells were lysed by sonication in buffer containing 0.05% NP-40. U33 snoRNP was 
isolated by antisense oligo mediated pull-down, with parallel sense oligo pull-down as control. 
Co-precipitating proteins were identified by mass spectrometry. Proteins with ≥ 2 peptides (for 
previously identified snoRNA binding proteins) or ≥ 5 peptides (for novel snoRNA binding 
proteins) and at least 2-fold enrichment in A versus S pull-down were considered specific 
snoRNP-associated proteins. *Previously identified snoRNA-interacting protein. 
 
Table 2.1: U33-associated proteins in whole cell sonicate
Description Gene Symbol
Number of 
Peptides 
(Whole cell; 
experiment 1)
Number of 
Peptides 
(Whole cell; 
experiment 2)
Heterogeneous nuclear ribonucleoprotein M Hnrnpm 191 313
*Heterogeneous nuclear ribonucleoprotein A1 Hnrnpa1 85 322
Far upstream element-binding protein 2 Khsrp 92 222
*Heterogeneous nuclear ribonucleoproteins A2/B1 Hnrnpa2b1 87 192
Heterogeneous nuclear ribonucleoprotein A/B Hnrnpab 79 190
*Heterogeneous nuclear ribonucleoprotein A3 Hnrnpa3 48 198
*Heterogeneous nuclear ribonucleoprotein D0 Hnrnpd 57 182
Myelin expression factor 2 Myef2 56 121
Heterogeneous nuclear ribonucleoprotein A0 Hnrnpa0 39 104
Polyadenylate-binding protein 1 Pabpc1 40 88
*TAR DNA-binding protein 43 Tardbp 30 76
DAZ-associated protein 1 Dazap1 35 69
Uncharacterized protein Gm7964 Gm7964 27 64
Heterogeneous nuclear ribonucleoprotein Q Syncrip 23 57
Heterogeneous nuclear ribonucleoprotein F Hnrnpf 26 45
*Lupus La protein homolog Ssb 21 39
RNA binding protein fox-1 homolog 2 Rbfox2 28 32
*ELAV-like protein 1 Elavl1 11 48
RNA binding motif protein, X-linked-like-1 Rbmxl1 18 41
Cellular nucleic acid-binding protein Cnbp 7 51
Heterogeneous nuclear ribonucleoprotein R Hnrnpr 17 36
*Heterogeneous nuclear ribonucleoprotein U-like protein 2 Hnrnpul2 12 31
RNA-binding motif, single-stranded-interacting protein 1 Rbms1 13 29
Squamous cell carcinoma antigen recognized by T-cells 3 Sart3 7 32
*Transcriptional activator protein Pur-alpha Pura 11 27
Heterogeneous nuclear ribonucleoprotein H2 Hnrnph2 10 22
Poly(rC)-binding protein 2 Pcbp2 8 22
G-rich sequence factor 1 Grsf1 9 21
Splicing factor U2AF 65 kDa subunit U2af2 12 18
Threonine--tRNA ligase, mitochondrial Tars2 10 18
*Transcriptional activator protein Pur-beta Purb 10 17
*rRNA 2'-O-methyltransferase fibrillarin Fbl 6 19
Pre-mRNA-processing factor 19 Prpf19 7 16
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Protein Sf3b2 Sf3b2 10 12
Transformer-2 protein homolog beta Tra2b 7 12
THO complex subunit 4 Alyref 9 10
RNA-binding protein 39 Rbm39 5 11
Zinc finger Ran-binding domain-containing protein 2 Zranb2 7 7
RNA-binding motif, single-stranded-interacting protein 2 Rbms2 5 8
*Nucleolar protein 58 NOP58 2 6
*U3 small nucleolar ribonucleoprotein protein MPP10 Mphosph10 2 5
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Figure 2.4: U33 binds different proteins depending on subcellular compartment and 
lipotoxicity 
NIH-3T3 cells were treated with 500 µM palmitate or vehicle (veh) for 12 hours.  
A. Cytosol was recovered by differential degergent extraction using digitonin buffer. Cytosolic 
RNA was analyzed for Rpl13a snoRNAs relative to Rplp0 by RTqPCR.  
B-F. Cytoslic (cyto) and post-cytosolic lysates (post-cyto) were generated by Dounce 
homogenization and sonication, respectively, in buffer containing 0.05% NP-40.  
B. Protein markers for cytosol (hsp90) and nucleus (nucleophosmin [npm] and histone h3 [H3]) 
were analyzed by western blot.  
C. Nuclear RNA marker U6 was quantified by RTqPCR in cyto and post-cyto lysates.   
D. Endogenous U33 snoRNPs were isolated with antisense oligo (ASO) using parallel pull-down 
with sense oligo as control. Graph reports quantification of snoRNAs in pull-down as recovery 
with ASO relative to sense oligo.  
E. Proteins co-precipitating with antisense (A) and sense (S) oligos were separated by 
polyacrylamide gel electrophoresis and visualized with SYPRO Ruby.  
F. Proteins in pull-downs were identified by mass spectrometry. Proteins with ³ 5 peptides and 
at least 2-fold enrichment in A versus S pull-down were considered specific snoRNP-associated 
proteins. Venn diagram reports the number of proteins associated with U33 only in the cytosol 
during lipotoxicity (palm, cyto; n = 27), proteins associated with U33 only in the post-cytosol 
fraction under homeostatic conditions (veh, post-cyto, n = 16), and proteins associated with U33 
under both conditions (n = 24). 
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Table 2.2: Proteins associated with U33 uniquely in cytosol during lipotoxicity 
NIH-3T3 cells were treated with 500 µM palmitate or vehicle. Cytoslic (cyto) and post-cytosolic 
lysates (post-cyto) were generated by Dounce homogenization (cyto) and sonication of 
remaining organelles in buffer containing 0.05% NP-40 as in Figure 2.4. U33 snoRNP was 
isolated by antisense oligo mediated pull-down, with parallel sense oligo pull-down as control. 
Co-precipitating proteins were identified by mass spectrometry. Proteins with ³ 5 peptides and 
at least 2-fold enrichment in A versus S pull-down were considered specific snoRNP-associated 
proteins. Table shows proteins that associate with U33 in the cytosol during lipotoxicity, but do 
not associate with U33 in the post-cytosol under homeostatic condition. 
 
 
Description
Gene 
Symbol
Peptide 
Count 
(Cyto; 
palm) Function
Far upstream element-binding protein 2 Khsrp 106
RNA binding; mRNA metabolism; mRNA 
regulation through AU-rich elements
Far upstream element-binding protein 3 Fubp3 73 RNA binding; transcription regulation
RNA-binding motif, single-stranded-interacting protein 1 Rbms1 41 RNA binding
Heterogeneous nuclear ribonucleoprotein U Hnrnpu 34
RNA binding; mRNA regulation through AU-
rich elements
Transcriptional activator protein Pur-beta Purb 18 transcription regulation
Polymerase I and transcript release factor Ptrf 17
transcription regulation, termination; 
caveolae formation
Ras GTPase-activating protein-binding protein 1 G3b1 17
stress granule regulation; Wnt signaling 
regulation
Elongation factor 1-alpha 1 Eef1a1 16 translation elongation
Caprin-1 Caprin1 15
translation regulation; stress granule 
component
Cellular nucleic acid-binding protein Cnbp 12 transcription regulation
Zinc finger Ran-binding domain-containing protein 2 Zranb2 12 transcription regulation
RNA-binding motif, single-stranded-interacting protein 2 Rbms2 11 Alternative splicing factor
Replication protein A 70 kDa DNA-binding subunit Rpa1 11 DNA replication; DNA repair
Probable ATP-dependent RNA helicase DHX36 Dhx36 9
transcription regulation; mRNA stability 
regulation through AU-rich elements
Ras GTPase-activating protein-binding protein 2 G3bp2 8 mRNA transport
High mobility group protein HMG-I/HMG-Y Hmga1 8
transcription regulation; heterochromatic 
organization
Small nuclear ribonucleoprotein Sm D3 Snrpd3 7 Core spliceosome component
Protein PRRC2C Prrc2c 7 RNA binding; hematopoietic differentiation
THO complex subunit 4 Alyref 6 RNA export
Exosome complex exonuclease RRP44 Dis3 6
Exonuclease; degradation of AU-rich element 
containing mRNA
Serine/threonine-protein kinase DCLK1 Dclk1 6 Microtubule regulation; neuronal migration
Heterogeneous nuclear ribonucleoprotein F Hnrnpf 5 alternative splicing regulation
Small nuclear ribonucleoprotein Sm D1 Snrpd1 5 Core spliceosome component
tRNA-splicing ligase RtcB homolog Rtcb 5 tRNA splicing
MAP7 domain-containing protein 1 Map7d1 5 microtubule assembly and stability
RNA-binding protein NOB1 Nob1 5 ribosome assembly
Serum deprivation-response protein Sdpr 5 caveolae maintenance
Table 2.2: Proteins associated with U33 uniquely in cytosol during lipotoxicity
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Table 2.3: Proteins associated with U33 uniquely in post-cytosol fraction under 
homeostatic conditions 
NIH-3T3 cells were treated with 500 µM palmitate or vehicle. Cytoslic (cyto) and post-cytosolic 
lysates (post-cyto) were generated by Dounce homogenization and sonication in buffer 
containing 0.05% NP-40 as in Figure 2.4. U33 snoRNP was isolated by antisense oligo 
mediated pull-down, with parallel sense oligo pull-down as control. Co-precipitating proteins 
were identified by mass spectrometry. Proteins with ³ 5 peptides and at least 2-fold enrichment 
in A versus S pull-down were considered specific snoRNP-associated proteins. Table shows 
proteins that associate with U33 in the post-cytosol under homeostatic conditions, but do not 
associate with U33 in the cytosol during lipotoxicity. 
 
 
Description
Gene 
Symbol
Peptide 
Count (Post-
cyto; veh) Function
RNA binding motif protein, X-linked-like-1 Rbmxl1 38 RNA splicing (possible)
Uncharacterized protein Gm7964 Gm7964 31 RNA binding
Heterogeneous nuclear ribonucleoprotein H2 Hnrnph2 21 Alternative splicing
Heterogeneous nuclear ribonucleoprotein Q Syncrip 17 RNA stability; RNA editing
ELAV-like protein 1 Elavl1 17 mRNA regulation through AU-rich elements
Splicing factor, proline- and glutamine-rich Sfpq 14 RNA splicing; transcriptional repression
G-rich sequence factor 1 Grsf1 14 mitocholdrial translation
Protein Sf3b2 Sf3bp2 12 RNA splicing
Heterogeneous nuclear ribonucleoprotein U-like protein 2 Hnrnpul2 12 DNA damage repair
RNA-binding protein FUS Fus 8 RNA splicing
Splicing factor U2AF 65 kDa subunit U2af2 8 RNA splicing; mRNA export
RNA-binding protein Raly Raly 7 RNA binding
Keratin, type II cytoskeletal 7 Krt7 6 Cell structure
U2 small nuclear ribonucleoprotein B'' Snrpb2 6 RNA splicing
Splicing factor 1 Sf1 5 RNA splicing; transcriptional repression
Serine/arginine-rich splicing factor 7 Srsf7 5 RNA splicing
Table 2.3: Proteins associated with U33 uniquely in post-cytosol fraction under homeostatic conditions
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Table 2.4: Proteins associated with U33 in both post-cytosol under homeostatic 
conditions and cytosol during lipotoxicity 
NIH-3T3 cells were treated with 500 µM palmitate or vehicle. Cytoslic (cyto) and post-cytosolic 
lysates (post-cyto) were generated by Dounce homogenization and sonication in buffer 
containing 0.05% NP-40 as in Figure 2.4. U33 snoRNP was isolated by antisense oligo 
mediated pull-down, with parallel sense oligo pull-down as control. Co-precipitating proteins 
were identified by mass spectrometry. Proteins with ³ 5 peptides and at least 2-fold enrichment 
in A versus S pull-down were considered specific snoRNP-associated proteins. Table shows 
proteins that associate with U33 in both cytosol during lipotoxicity and post-cytosol under 
homeostatic conditions. 
 
 
Description
Gene 
Symbol
Peptide 
Count (Cyto; 
palm)
Peptide 
Count (Post-
cyto; veh)
Heterogeneous nuclear ribonucleoprotein M Hnrnpm 286 162
Heterogeneous nuclear ribonucleoprotein A1 Hnrnpa1 102 377
Heterogeneous nuclear ribonucleoproteins A2/B1 Hnrnpa2b1 80 223
TAR DNA-binding protein 43 Tardbp 64 59
Heterogeneous nuclear ribonucleoprotein A3 Hnrnpa3 60 144
Uncharacterized protein Gm9242 Gm9242 56 140
DAZ associated protein 1, isoform CRA_b Dazap1 35 32
Putative RNA-binding protein 3 Rbm3 28 27
Myelin expression factor 2 Myef2 27 92
Heterogeneous nuclear ribonucleoprotein A0 Hnrnpa0 37 55
Histone H2B type 1-F/J/L Hist1h2bf 17 24
Heterogeneous nuclear ribonucleoprotein D0 Hnrnpd 135 176
Heterogeneous nuclear ribonucleoprotein D-like Hnrnpdl 12 31
Squamous cell carcinoma antigen recognized by T-cells 3 Sart3 8 15
Heterogeneous nuclear ribonucleoprotein A/B Hnrnpab 109 206
Heterogeneous nuclear ribonucleoprotein R Hnrnpr 6 23
Lupus La protein homolog Ssb 18 27
60S ribosomal protein L22 Rpl22 22 6
KH domain-containing, RNA-binding, signal transduction-associated protein 1 Khdrbs1 5 5
RNA binding protein fox-1 homolog 2 Rbfox2 9 18
Polyadenylate-binding protein 1 Pabpc1 32 18
40S ribosomal protein S17 Rps17 22 13
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 Ddx5 7 16
Protein Gm9493 Gm9493 64 22
Table 2.4: Proteins associated with U33 in both post-cytosol under homeostatic conditions and cytosol during 
lipotoxicity
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Figure 2.5: Validation of U33 interactions with KHSRP, hnRNP U, Caprin-1, and G3bp1 by 
ASO pull-down and western blotting  
NIH-3T3 cells were treated with 500 µM palmitate or vehicle. Cytosolic lysates were collected by 
Dounce homogenization as in Figure 2.4. U33 snoRNP was isolated by antisense oligo 
mediated pull-down, with parallel sense oligo pull-down as control. Graphs on left of each panel 
report recovered snoRNAs as quantified by RTqPCR for antisense oligo (ASO) pull-down 
relative to sense oligo.  
A. Recovered proteins were analyzed by western blot for hnRNP U and KHSRP. 
B. Recovered proteins were analyzed by western blot for Caprin-1 and G3bp1. 
hnRNP U
A
KHSRP
Caprin-1
G3bp1
cyto
AS S A
++ - -
oligo
palm
wh
ol
e c
ell
so
ni
ca
te
B
cyto
AS S A
++ - -
oligo
palm
wh
ol
e c
ell
so
ni
ca
te
veh palm
0
20
40
60
Re
lat
ive
 P
ull
do
wn
(A
SO
:s
en
se
)
U20
U33
U17b
FIGURE 2.5
veh palm
0
20
40
60
80
100
Re
lat
ive
 P
ull
do
wn
(A
SO
:s
en
se
)
U20
U33
U17b
 
 
34 
 
 
Figure 2.6: Validation of U33 interactions with KHSRP, hnRNP U, Caprin-1, and G3bp1 by 
immunoprecipitation and qRT-PCR 
NIH-3T3 cells were treated with 500 µM palmitate or vehicle. Cytosolic lysates were collected by 
Dounce homogenization as in Figure 2.4. Immunoprecipitation was performed with antibody to 
hnRNP U(A), KHSRP(B), Caprin-1(C), and G3bp1(D). Parallel immunoprecipitations with 
normal rabbit IgG served as negative controls. In each panel, blot above graph shows western 
analysis of immunoprecipitated proteins run alongside non-precipitated lysate. Graphs below 
report RTqPCR quantification of co-precipitating U33 or glutamate tRNA (glu-tRNA) as a ratio of 
RNA recovered with specific antibody relative to IgG.  
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Figure 2.7: hnRNP U accumulates in the cytoplasm during lipotoxic stress. 
NIH-3T3 cells were treated with 500 µM palmitate or vehicle. Cytosolic and post-cytosolic 
lysates were collected by Dounce homogenization and sonication, respectively, as in Figure 2.4. 
Recovered proteins were analyzed by western blot for hnRNP U and actin. 
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Chapter 3 
Changes in Gene Expression During 
Lipotoxicity 
 
3.1 Introduction 
Canonically, snoRNAs are found in the nucleolus, where they direct the chemical 
modification of rRNA by complementary base pairing to the target. However, many 
snoRNAs lack antisense complementarity to rRNA. Further, the snoRNAs MBII-52 and 
HBII-52 have been shown to direct alternative splicing of the serotonin receptor 2C 
through a mechanism that is proposed to involve direct modification of a non-canonical 
target – the pre-mRNA.92 Accumulation of the Rpl13a snoRNAs in the cytosol during 
lipotoxicity suggests that these snoRNAs may also target mRNAs, an abundant class of 
RNAs in the cytoplasm.42,97 We hypothesized that modifications of mRNAs may result in 
changes in the abundance or translation efficiency of some transcripts. In this chapter, 
we report the results of RNA-seq and ribosome profiling experiments to identify 
differential expression and translation of transcripts during lipotoxicity. 
 
3.2 Results 
In order to identify early changes in gene expression, RNA-seq was performed on NIH-
3T3 cells treated with palmitate or vehicle for 8 hours. At this time point, Rpl13a snoNAs 
are readily detected in the cytosol (Fig. 3.1A), but cells remain tightly adherent to the 
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culture dish, and there is no significant increase in cell death (data not shown). cDNA 
libraries were prepared from duplicate total RNA samples, from which rRNA was 
removed using RiboZero and sequencing was performed on an Illumina HiSeq 2500 
platform.  For the palmitate treated samples, the total number of reads was 
approximately 49 million and 51 million, which yielded 43 million and 45 million mapped 
reads. For the vehicle treated samples, the total number of reads was approximately 58 
million and 44 million, which yielded 53 million and 38 million mapped reads. DESeq2 
analysis indicated that transcripts for 194 genes were significantly upregulated by at 
least 2-fold, with a false discovery rate (FDR) <0.05 (Table 3.1). Transcripts for 28 
genes were significantly downregulated (FDR <0.05) and changed by at least 2-fold 
(Table 3.1). Of these, representative up- and down-regulated transcripts were chosen 
for RTqPCR validation in independent preparations of RNA from palmitate- and vehicle-
treated cells. All tested transcripts showed significant changes in abundance by 
RTqPCR that correlated with the direction of change found by RNA-seq (Fig. 3.1B). 
While the effect of palmitate treatment on gene expression has been extensively 
reported for pancreatic beta cells119-121 and hepatic-derived cells,122,123 our data provide 
new insights into changes in fibroblast gene expression during lipotoxicity.  
 
We used DAVID 6.7 to perform gene ontology (GO) analysis of differentially expressed 
transcripts following palmitate treatment.124,125 Among the differentially expressed 
transcripts, the term “genes that regulate transcription” was significantly over-
represented (FDR < 0.05) (Table 3.2). 36 differentially expressed genes corresponded 
to this biological process, including activating transcription factor 3 (Atf3), tribbles 
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homolog 3 (Trib3), heme oxygenase 1 (Hmox1), and basonuclin 1 (Bnc1).  Atf3, Trib3, 
and Hmox1 were all upregulated during lipotoxicity in fibroblasts, similar to results seen 
in pancreatic b cells following palmitate treatment.119  In addition to being previously 
linked to lipotoxicity, all three genes have been implicated in translation or the 
endoplasmic reticulum stress response.126-128 Bnc1 was downregulated by lipotoxic 
stress. Bnc1 is a zinc finger protein that has been linked to maintenance of proliferative 
capacity.129 Additionally, genes related to cell death and endoplasmic reticulum (ER) 
stress were highly represented, but these terms did not reach statistical significance. 18 
genes related to these biological processes included DNA-damage inducible transcript 3 
(Ddit3), CCAAT/enhancer binding protein beta (Cebpb), and ERO1-like (Ero1l). Ddit3, 
also known as Chop, is induced by ER stress and increases cellular ROS via the down-
regulation of Bcl-2.130 Cebpb mRNA levels are induced by ER stress, and the protein 
interferes with the pro-survival functions of ATF4 during stress.131  Ero1l is a resident 
ER protein that plays a role in oxidative protein folding.132 Previous studies of lipotoxicity 
in other cell types found that genes related to transcription, ER stress, lipid metabolism, 
and cell death were differentially expressed.119,122 Many of the differentially expressed 
genes in our study, including thioredoxin interacting protein, myelocytomatosis 
oncogene, Atf3, and growth arrest and DNA damage inducible 45a, were previously 
linked to lipotoxicity.119 Still other genes, including Ski-like, Fam129a, and Snail 
homolog 2, were previously linked to metabolism, stress, or cell death, but these results 
are the first linking their expression to lipotoxicity.  
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In view of our finding that U33 binds proteins known to regulate transcripts through 
AREs (KHSRP and hnRNP U), we also examined whether regulated transcripts contain 
AREs using AREsite 1.0 (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi).133 Remarkably, 
while only 8-16% of the transcriptome contains AREs,133,134 33% of the transcripts 
differentially expressed during lipotoxicity have AREs in their 3’-UTRs (Table 3.1). 
Furthermore, Gene Set Enrichment Analysis135,136 indicated that genes containing 
seven related ARE consensus sequences are upregulated in palmitate treated cells 
(Table 3.3). These results suggest that palmitate treatment regulates abundance of 
specific functional classes of transcripts and that regulation of gene expression could 
relate to the presence of AREs in regulated transcripts. 
 
AREs are known to mediate regulation of gene expression through changes in transcript 
half-life.137,138 To test whether the regulation of transcript abundance was related to 
changes in transcript half-life, we performed metabolic labeling. Cells were pulsed with 
ethynyl uridine then chased with ethynyl uridine-free media under palmitate-treated or 
control conditions. Following harvest of total cellular RNA, ethynyl uridine-containing 
RNA was labeled with biotin, captured with streptavidin, and quantified by RTqPCR for 
several regulated mRNAs. Stability of individual transcripts was estimated by comparing 
the quantity of labeled RNA immediately after the pulse and following the chase for the 
samples collected under lipotoxic and control conditions. RNA-seq showed transcripts 
for Ppp1r15a, Ddit3, and Ptx3 were upregulated during lipotoxicity. Each of these 
transcripts had increased stability during chase under lipotoxic conditions compared to 
control (Fig. 3.2).  RNA-seq showed that the transcript for Fasn was downregulated.  
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This transcript had decreased stability during lipotoxicity compared to control chase 
conditions. The transcript for Rplp0, which was not differentially expressed during 
lipotoxicity as quantified by RNA-seq, did not show any change in stability with palmitate 
treatment. These results suggest that changes in RNA stability may play a role in the 
abundance of transcripts that are differentially expressed during lipotoxicity.  
 
The genetic screen in which the Rpl13a snoRNAs were identified also identified eEF1A-
1 as a critical gene in lipotoxicity.36 Given that eEF1A1 plays a role in peptide 
elongation, we hypothesized that changes in translation efficiency could also contribute 
to the biology of the lipotoxic response. In order to investigate this hypothesis, we used 
a recently published ribosome profiling protocol.139 In parallel to the mRNA collected for 
the RNA-seq described above under basal and lipotoxic conditions, we recovered 
ribosome footprints, which are mRNA fragments protected from RNase digestion by the 
presence of ribosomes, a feature of actively translated messages. The footprints were 
used to construct cDNA libraries and sequenced on an Illumina HiSeq 2500 platform. 
For the palmitate treated samples, the total number of reads was approximately 35 
million and 27 million, which yielded 21 million and 13 million mapped reads. For the 
vehicle treated samples, the total number of reads was approximately 33 million and 36 
million, which yielded 21 million and 16 million mapped reads. DEseq2 analysis yielded 
a list of 63 transcripts with significant differential footprint abundance under basal and 
lipotoxic conditions (Table 3.4). To gauge translation efficiency, the relative read counts 
for footprint abundance were normalized for relative read counts for transcript 
abundance for each gene. We found 211 genes with a greater than 2-fold difference in 
 
 
41 
the effect of palmitate on transcript abundance versus ribosome footprint abundance 
(Fig. 3.3). This finding indicates that lipotoxicity regulates gene expression not just at 
the level of transcription, but also at the level of translation. 
  
Many previously published analyses of translation efficiency with ribosome footprinting 
have relied on either a single sample set or biological duplicates, and the limited 
statistical power given by these small sample sizes has limited analysis 
approaches.140,141 Although we also sequenced and analyzed samples in duplicate, we 
have developed a method to calculate statistical significance of changes in translational 
efficiency. Following earlier approaches on analysis of RNA-Seq data,142 we pooled 
read counts for genes in duplicated samples after normalizing to account for varying 
sequencing depth, then constructed a fitted bivariate negative binomial distribution from 
this count data under the assumption of equal translational efficiency in control vs. 
treated cells. P-values were then calculated as the tail probability of this fitted 
distribution given the count data and corrected for multiple hypothesis testing using the 
Benjamini-Hochberg method to give a false discovery rate of 5%. To resolve the limited 
statistical power of small sample sizes, we used a maximum a posteriori estimate for 
gene-specific sample variance under each condition, using an exponential prior 
distribution of the sample variance. Using this approach, we identified 65 genes whose 
transcripts undergo significant differential translation efficiency with at least a 2-fold 
change during lipotoxicity (Table 3.5). Ten of these transcripts are more efficiently 
translated during lipotoxicity, while 55 are less efficiently translated. 
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We identified gene ontology (GO) terms associated with each differentially translated 
transcript with Panther 10.0.143-145 The terms cell communication, cell cycle, apoptotic 
process, protein folding, and translation were each associated with several genes that 
were differentially translated. The transcript with the largest increase in translational 
efficiency was Rad21. Its protein product is cleaved by caspases 3 and 7 as an early 
apoptotic event, and the resulting cleavage products are hypothesized contributors to 
induction of apoptosis, possibly through dissociation from DNA.146 The P4hb transcript, 
which encodes a protein disulfide isomerase (PDI), was translated much less efficiently 
during lipotoxic stress. PDI is a pro-apoptotic protein shown to induce Bak 
oligomerization.147 The Tp53 transcript, encoding the p53 protein, underwent one of the 
most significant decreases (p<0.0001) in translation efficiency. The extensively studied 
p53 protein is a key player in the apoptotic pathway in response to certain stimuli, and 
its levels are tightly controlled.148 Decreased p53 results in a pro-survival phenotype;149 
the decrease in p53 translation efficiency during early lipotoxic stress could be part of 
an attempt at adaptation by the cell. These results further underscore the likelihood that 
translational control plays a role in the cellular response to lipotoxic stress. 
 
3.3 Concluding Remarks and Future Directions 
RNA-seq of palmitate- and vehicle-treated NIH-3T3 fibroblasts has identified 222 
differentially expressed genes. While many of the changes in expression matched 
results seen in other cell types under lipotoxic conditions, we identified several novel 
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lipotoxicity-regulated genes. Additionally, metabolic labeling has shown that changes in 
mRNA stability contribute to the changes in transcript levels due to palmitate treatment. 
One third of the genes that are differentially expressed during lipotoxicity contain AREs. 
The role of these sequence elements in mediating changes in transcript levels during 
lipotoxicity, and whether transcript stability is mediated by the ARE-binding proteins 
found to bind U33, will be tested in future studies. 
 
Ribosome profiling analysis indicated that gene expression during lipotoxicity is 
regulated at the level of translation, with 65 transcripts undergoing significant changes 
in translation efficiency following palmitate treatment. We have developed a novel 
analysis pipeline to identify statistically significant changes in translation efficiency. 
Additional studies will be needed to test this method in an independent sample set and 
to validate that the observed changes in translational efficiency result in changes in 
protein levels. 
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Figure 3.1 Differential gene expression analysis of NIH-3T3 cells during lipotoxicity 
A. NIH-3T3 cells were treated with 500 µM palmitate (palm) or vehicle (veh) for 8h. Cytosolic 
RNA was collected following differential detergent extraction using digitonin buffer. Cytosolic 
RNA was analyzed for Rpl13a snoRNAs relative to Rplp0 by RTqPCR. Graph represents mean 
value from two independent experiments. 
B. NIH-3T3 cells were treated with 500 µM palmitate or vehicle. RTqPCR validation of changes 
in abundance, normalized to Rplp0, of select transcripts identified by RNA-seq. Graph 
represents mean values + SE from 3 independent experiments. (Ppp1r15a: protein 
phosphatase 1, regulatory subunit 15A; Gadd45a: growth arrest and DNA-damage-inducible, 
alpha; Sqstm1: sequestosome 1; Fasn: fatty acid synthase) 
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Table 3.1: Early changes in RNA abundance during lipotoxicity 
NIH-3T3 cells were treated for 8h with 500 µM palmitate or vehicle. Table reports significantly 
differentially expressed genes with > 2-fold change in RNA abundance. The presence of AU-
rich elements (AREs) in 3’-UTRs was queried for each gene using ARE-site 1.0. 
 
 
 
 
 
 
Gene Symbol Gene Description
P-value 
(adjusted)
Fold 
Change
Contains 
ARE
Atf3 activating transcription factor 3 1.348E-99 22
Car6 carbonic anhydrase 6 1.9125E-37 12.3
Gadd45a growth arrest and DNA-damage-inducible 45 alpha 1.0646E-92 9.8
Ppp1r15a protein phosphatase 1, regulatory (inhibitor) subunit 15A 3.374E-127 9.7 +
Sh2d6 SH2 domain containing 6 1.2912E-24 9.1
Fibin fin bud initiation factor homolog (zebrafish) 1.79E-13 9 +
Gm17173 predicted gene 17173 4.1365E-10 8.6
Trib3 tribbles homolog 3 (Drosophila) 4.4998E-78 7.2
Slc7a11
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 11 3.8082E-46 6.8
Napb
N-ethylmaleimide sensitive fusion protein attachment protein 
beta 1.0815E-45 6.5
Lif leukemia inhibitory factor 3.9399E-37 6.4 +
Acot2 acyl-CoA thioesterase 2 9.5184E-59 6.4
Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1 1.7808E-08 6.3
Rab39b RAB39B, member RAS oncogene family 3.5568E-18 6 +
Angptl6 angiopoietin-like 6 1.3459E-14 5.9
Chac1 ChaC, cation transport regulator 1 9.0637E-57 5.7 +
Vldlr very low density lipoprotein receptor 3.7174E-35 5.2
Ddit3 DNA-damage inducible transcript 3 1.1726E-49 5.1
Abca8b ATP-binding cassette, sub-family A (ABC1), member 8b 3.7903E-07 5
Sh3bgrl2 SH3 domain binding glutamic acid-rich protein like 2 1.634E-06 5
Arid5a AT rich interactive domain 5A (MRF1-like) 1.0342E-36 5
Hmox1 heme oxygenase (decycling) 1 1.3252E-39 4.9 +
P2rx7 purinergic receptor P2X, ligand-gated ion channel, 7 5.6509E-07 4.7
Cth cystathionase (cystathionine gamma-lyase) 8.0714E-39 4.4
Tnfsf18 tumor necrosis factor (ligand) superfamily, member 18 9.9276E-05 4.2 +
Nfil3 nuclear factor, interleukin 3, regulated 4.9827E-28 4.2 +
Adamtsl3 ADAMTS-like 3 3.1895E-05 4.2
Soat2 sterol O-acyltransferase 2 4.6613E-10 4 +
Casp4 caspase 4, apoptosis-related cysteine peptidase 5.4869E-16 4
Stard5 StAR-related lipid transfer (START) domain containing 5 5.2669E-36 4
Slc6a9
solute carrier family 6 (neurotransmitter transporter, glycine), 
member 9 1.9837E-30 3.9
Ptx3 pentraxin related gene 8.9421E-12 3.8 +
2410006H16Rik RIKEN cDNA 2410006H16 gene 1.9002E-49 3.8
Stbd1 starch binding domain 1 1.2405E-09 3.7
P2rx3 purinergic receptor P2X, ligand-gated ion channel, 3 7.1151E-06 3.6 +
Mtm1 X-linked myotubular myopathy gene 1 5.5181E-19 3.6 +
Plek pleckstrin 6.1197E-06 3.6
Gtpbp2 GTP binding protein 2 2.7583E-35 3.5 +
Rgs16 regulator of G-protein signaling 16 1.2564E-06 3.5 +
Table 3.1 Early changes in RNA abundance during lipotoxicity
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Ddit4 DNA-damage-inducible transcript 4 2.2314E-17 3.5 +
Pdk4 pyruvate dehydrogenase kinase, isoenzyme 4 1.1314E-30 3.5
Slc3a2
solute carrier family 3 (activators of dibasic and neutral amino 
acid transport), member 2 5.9398E-43 3.4
Cdsn corneodesmosin 0.00204192 3.4
Btg2 B cell translocation gene 2, anti-proliferative 2.1249E-15 3.3 +
Ets2 E26 avian leukemia oncogene 2, 3' domain 1.1084E-27 3.3
Socs2 suppressor of cytokine signaling 2 8.8896E-14 3.2 +
Klf11 Kruppel-like factor 11 2.0499E-15 3.2 +
Gch1 GTP cyclohydrolase 1 0.00017766 3.2 +
Dnmt3l DNA (cytosine-5-)-methyltransferase 3-like 8.1039E-05 3.1
Sesn2 sestrin 2 3.2598E-26 3.1
Txnip thioredoxin interacting protein 7.0358E-16 3.1
Sqstm1 sequestosome 1 4.0545E-41 3.1
Herpud1
homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1 2.7364E-34 3.1
Fas Fas (TNF receptor superfamily member 6) 8.3365E-05 3.1
Cxcl1 chemokine (C-X-C motif) ligand 1 6.9033E-06 3 +
Gpt2 glutamic pyruvate transaminase (alanine aminotransferase) 2 4.1008E-29 3
Zfp945 zinc finger protein 945 7.4754E-17 3
Relb avian reticuloendotheliosis viral (v-rel) oncogene related B 7.3733E-20 3
Hectd2 HECT domain containing 2 2.4207E-09 2.9 +
Akna AT-hook transcription factor 1.1482E-16 2.9 +
Tlr2 toll-like receptor 2 1.662E-05 2.9
Dlg2 discs, large homolog 2 (Drosophila) 0.00038158 2.9
Gm10557 predicted gene 10557 0.00018353 2.9
Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 1.3352E-19 2.9
Trp53inp1 transformation related protein 53 inducible nuclear protein 1 9.1844E-11 2.8 +
Prl2c1 Prolactin family 2, subfamily c, member 1 0.00260328 2.8 +
Aldh1l2 aldehyde dehydrogenase 1 family, member L2 1.1705E-15 2.8 +
Otub2 OTU domain, ubiquitin aldehyde binding 2 7.8783E-13 2.8 +
Ndrg1 N-myc downstream regulated gene 1 1.4104E-18 2.8
Psph phosphoserine phosphatase 5.947E-27 2.8
Jhdm1d
jumonji C domain-containing histone demethylase 1 homolog D 
(S. cerevisiae) 1.5428E-14 2.8
Tulp2 tubby-like protein 2 0.00489871 2.8
Calcrl calcitonin receptor-like 3.0654E-10 2.8
Zfp184 zinc finger protein 184 (Kruppel-like) 5.123E-06 2.8
Gm6806 predicted gene 6806 0.00035806 2.8
Nupr1 nuclear protein transcription regulator 1 2.5799E-27 2.8
Slc1a4
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 1.3383E-31 2.8
4922501C03Rik RIKEN cDNA 4922501C03 gene 1.5331E-15 2.7
Dhrs9 dehydrogenase/reductase (SDR family) member 9 3.8071E-17 2.7
1500012F01Rik RIKEN cDNA 1500012F01 gene 3.5614E-28 2.7
Chka choline kinase alpha 3.558E-22 2.7
Ero1l ERO1-like (S. cerevisiae) 2.935E-25 2.6 +
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Il1rl2 interleukin 1 receptor-like 2 0.00057107 2.6 +
Nnmt nicotinamide N-methyltransferase 1.5607E-05 2.6
Elavl2
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 (Hu 
antigen B) 5.6665E-08 2.6
Cd46 CD46 antigen, complement regulatory protein 0.00190554 2.6
Cyb5r1 cytochrome b5 reductase 1 7.6321E-24 2.6
Ppef1 protein phosphatase with EF hand calcium-binding domain 1 0.00122474 2.6
Gm15676 predicted gene 15676 0.00023709 2.6
Arrdc4 arrestin domain containing 4 5.7316E-12 2.6
Mmp28 matrix metallopeptidase 28 (epilysin) 0.00687466 2.6
Paqr3 progestin and adipoQ receptor family member III 1.9219E-07 2.5 +
Gm12258 predicted gene 12258 8.7082E-07 2.5 +
Ddx26b DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26B 9.8859E-12 2.5 +
Pck2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 4.2982E-24 2.5
Mib2 mindbomb homolog 2 (Drosophila) 1.5097E-13 2.5
Clcn3 chloride channel 3 3.9567E-12 2.5
Gm15834 predicted gene 15834 0.00026137 2.5
Apobr apolipoprotein B receptor 2.4654E-06 2.4 +
Dennd4a DENN/MADD domain containing 4A 1.751E-12 2.4 +
Them4 thioesterase superfamily member 4 7.5795E-07 2.4 +
Grem1 gremlin 1 7.2878E-13 2.4 +
Tmem154 transmembrane protein 154 6.0886E-05 2.4 +
Hhipl1 hedgehog interacting protein-like 1 2.2823E-07 2.4 +
Pappa2 pappalysin 2 0.00089663 2.4 +
Fam110c family with sequence similarity 110, member C 2.7584E-15 2.4
Rnd1 Rho family GTPase 1 5.9176E-15 2.4
Stc2 stanniocalcin 2 2.2739E-14 2.4
Myc myelocytomatosis oncogene 2.4518E-19 2.4
Plk2 polo-like kinase 2 3.7213E-20 2.4
Gm129 predicted gene 129 0.00010292 2.4
Dus4l dihydrouridine synthase 4-like (S. cerevisiae) 7.0413E-09 2.4
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 8.5782E-06 2.4
Pde1a phosphodiesterase 1A, calmodulin-dependent 0.00402413 2.4
Phf10 PHD finger protein 10 1.3352E-19 2.4
Dhrs7 dehydrogenase/reductase (SDR family) member 7 1.1775E-08 2.4
Cebpβ CCAAT/enhancer binding protein (C/EBP), beta 8.8896E-14 2.4
D8Ertd82e DNA segment, Chr 8, ERATO Doi 82, expressed 6.3491E-13 2.4
Rora RAR-related orphan receptor alpha 1.4056E-05 2.3 +
Prl2c5 prolactin family 2, subfamily c, member 5 0.00011491 2.3 +
Lonp1 lon peptidase 1, mitochondrial 5.0046E-21 2.3
Aff1 AF4/FMR2 family, member 1 1.1239E-17 2.3
Tspyl4 TSPY-like 4 2.6188E-09 2.3
Cd209c CD209c antigen 5.8789E-08 2.3
Zfp493 zinc finger protein 493 0.0042491 2.3
Psd3 pleckstrin and Sec7 domain containing 3 6.602E-07 2.3
1500002C15Rik RIKEN cDNA 1500002C15 gene 0.00019733 2.3
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Nfkbie
nuclear factor of kappa light polypeptide gene enhancer in B 
cells inhibitor, epsilon 4.0193E-05 2.3
Zfp951 zinc finger protein 951 0.00934122 2.2 +
Rhbdd1 rhomboid domain containing 1 5.7973E-13 2.2 +
AC107744.1 None 1.0047E-13 2.2 +
Usp53 ubiquitin specific peptidase 53 1.7223E-11 2.2 +
Manea mannosidase, endo-alpha 1.6268E-08 2.2 +
Nfxl1 nuclear transcription factor, X-box binding-like 1 3.5348E-08 2.2 +
Spry3 sprouty homolog 3 (Drosophila) 2.6316E-06 2.2
Fam53b family with sequence similarity 53, member B 0.0083614 2.2
Rsbn1 rosbin, round spermatid basic protein 1 1.5341E-12 2.2
Zc3h6 zinc finger CCCH type containing 6 8.9181E-05 2.2
Vegfa vascular endothelial growth factor A 2.2682E-15 2.2
Dgat2 diacylglycerol O-acyltransferase 2 0.00287386 2.2
1810032O08Rik RIKEN cDNA 1810032O08 gene 1.0028E-08 2.2
Slc38a7 solute carrier family 38, member 7 1.8219E-13 2.2
Nfkbia
nuclear factor of kappa light polypeptide gene enhancer in B 
cells inhibitor, alpha 1.2104E-10 2.2
Hmcn1 hemicentin 1 0.00412682 2.2
Gm21092 predicted gene, 21092 5.9799E-14 2.2
Chd2 chromodomain helicase DNA binding protein 2 3.222E-12 2.1 +
Syne1 spectrin repeat containing, nuclear envelope 1 1.2512E-06 2.1 +
Taf15
TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor 1.5201E-06 2.1 +
Gm21811 predicted gene, 21811 3.9784E-05 2.1 +
Eda2r ectodysplasin A2 receptor 9.8814E-09 2.1 +
CT030166.1 None 1.1545E-05 2.1 +
Cpox coproporphyrinogen oxidase 2.6548E-11 2.1 +
Mitf microphthalmia-associated transcription factor 0.00063436 2.1
Slc7a5
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 5 2.152E-14 2.1
Dnajb9 DnaJ (Hsp40) homolog, subfamily B, member 9 7.3011E-07 2.1
Mdfic MyoD family inhibitor domain containing 8.7612E-14 2.1
Lyst lysosomal trafficking regulator 1.8589E-09 2.1
Arhgef2 rho/rac guanine nucleotide exchange factor (GEF) 2 1.7299E-14 2.1
Junb Jun-B oncogene 4.3091E-07 2.1
Stam
signal transducing adaptor molecule (SH3 domain and ITAM 
motif) 1 3.0818E-13 2.1
2810474O19Rik RIKEN cDNA 2810474O19 gene 1.9017E-10 2.1
Cnnm4 cyclin M4 4.2178E-09 2.1
Npr3 natriuretic peptide receptor 3 2.275E-07 2.1
Glce glucuronyl C5-epimerase 6.2414E-15 2.1
A630007B06Rik RIKEN cDNA A630007B06 gene 1.1309E-10 2.1
Garem GRB2 associated, regulator of MAPK1 2.7012E-07 2.1
Cpt1a carnitine palmitoyltransferase 1a, liver 1.1992E-12 2.1
Sash1 SAM and SH3 domain containing 1 7.5194E-12 2.1
Zbtb10 zinc finger and BTB domain containing 10 3.605E-08 2.1
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Klhl24 kelch-like 24 7.3481E-09 2 +
Tigd2 tigger transposable element derived 2 2.7207E-07 2 +
Pnrc2 proline-rich nuclear receptor coactivator 2 3.9716E-10 2 +
Htra1 HtrA serine peptidase 1 0.00562568 2 +
Gadd45b growth arrest and DNA-damage-inducible 45 beta 1.6687E-11 2 +
Stk40 serine/threonine kinase 40 7.9161E-09 2 +
Sgtb
small glutamine-rich tetratricopeptide repeat (TPR)-containing, 
beta 3.1222E-06 2 +
Fam171b family with sequence similarity 171, member B 9.4877E-06 2
Pycr1 pyrroline-5-carboxylate reductase 1 2.9381E-07 2
AC155814.1 None 0.0087947 2
Fam129a family with sequence similarity 129, member A 0.00049161 2
3110043O21Rik RIKEN cDNA 3110043O21 gene 2.1347E-08 2
Clec2d C-type lectin domain family 2, member d 1.2337E-10 2
Fbxl12 F-box and leucine-rich repeat protein 12 3.7147E-05 2
Igfbp4 insulin-like growth factor binding protein 4 6.1271E-06 2
Tgif1 TGFB-induced factor homeobox 1 2.6099E-12 2
Skil SKI-like 2.7634E-13 2
Snai2 snail homolog 2 (Drosophila) 5.7541E-05 2
Wisp1 WNT1 inducible signaling pathway protein 1 3.2186E-12 2
Murc muscle-related coiled-coil protein 0.00021647 2
Ugt1a6a UDP glucuronosyltransferase 1 family, polypeptide A6A 0.00294592 2
Fam135a family with sequence similarity 135, member A 6.3649E-09 2
Zyg11b zyg-ll family member B, cell cycle regulator 4.8993E-14 2
Trim46 tripartite motif-containing 46 6.7438E-05 2
Deptor DEP domain containing MTOR-interacting protein 0.0067323 2
Irs1 insulin receptor substrate 1 3.6415E-12 -2 +
Cxcr7 chemokine (C-X-C motif) receptor 7 6.8284E-09 -2 +
Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 6.6689E-05 -2 +
Ccne1 cyclin E1 2.4079E-07 -2 +
Klhdc8a kelch domain containing 8A 1.776E-07 -2
Tmem50b transmembrane protein 50B 5.9096E-06 -2
Tinagl1 tubulointerstitial nephritis antigen-like 1 1.3831E-09 -2
Metrnl meteorin, glial cell differentiation regulator-like 6.8517E-10 -2
Cd248 CD248 antigen, endosialin 2.2833E-11 -2
Gjb3 gap junction protein, beta 3 3.4221E-07 -2
Ccsap centriole, cilia and spindle associated protein 3.9472E-06 -2
Oaf OAF homolog (Drosophila) 6.2856E-08 -2
Bnc1 basonuclin 1 9.1486E-09 -2.1 +
Lfng LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 0.00037626 -2.1 +
Fasn fatty acid synthase 3.5029E-13 -2.1
AC158898.1 uncharacterized protein 0.0055034 -2.1
Acpl2 acid phosphatase-like 2 1.1768E-05 -2.1
Spon2 spondin 2, extracellular matrix protein 7.9585E-10 -2.2 +
Synpo synaptopodin 2.4285E-11 -2.2 +
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Klk10 kallikrein related-peptidase 10 0.00020662 -2.2
Apln apelin 2.1055E-09 -2.2
Cdc42ep2 CDC42 effector protein (Rho GTPase binding) 2 2.5234E-13 -2.3 +
Rnf145 ring finger protein 145 7.8821E-16 -2.3 +
Chst12 carbohydrate sulfotransferase 12 0.00015234 -2.3
Ror1 receptor tyrosine kinase-like orphan receptor 1 0.00053053 -2.4 +
4930483K19Rik RIKEN cDNA 4930483K19 gene 0.00247085 -2.7 +
Plau plasminogen activator, urokinase 2.87E-10 -2.7
Mycn
v-myc myelocytomatosis viral related oncogene, neuroblastoma 
derived (avian) 0.00119294 -2.8
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Table 3.2: DAVID gene ontology analysis of genes differentially expressed during 
lipotoxicity.  
All genes with significant differential expression during lipotoxicity were analyzed by DAVID 6.7 
with all detected genes as background. Table shows results for biological processes previously 
implicated in lipotoxicity. Gene count is number of differentially expressed genes for each 
process. 
 
 
  
Biological Process GO Identifier Gene Count FDR
Regulation of Transcription GO:0045449 36 0.0420
Regulation of Cell Death GO:0010941 15 0.0804
Response to Protein Stimulus GO:0051789 6 0.0741
Induction of Programmed Cell Death GO:0012502 8 0.0763
Response to Endoplasmic Reticulum Stress GO:0034976 4 0.1289
Table 3.2 DAVID Gene Ontology Analysis of Genes Differentially Expressed During Lipotoxicity
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Table 3.3: Upregulation of ARE-containing transcripts by consensus sequence during 
lipotoxicity 
Gene set enrichment analysis (GSEA) was performed on RNA-seq data with genes containing 
each ARE consensus sequence as custom gene sets. Table shows results for analysis with 
10,000 gene-set permutations. 
 
 
 
  
                
ARE Consensus Sequence FDR 
WWTATTTATWW <0.0007
WWWATTTAWWW <0.0007
WWWWATTTAWWWW <0.0007
WWWTATTTATWWW 0.000025
WTATTTATW 0.0001
TTATTTATT 0.0001
WWATTTAWW 0.000486
Table 3.3 Upregulation of ARE-containing transcript  by consensu sequence during lipotoxicity
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Figure 3.2 Changes in transcript stability parallel changes in abundance 
NIH-3T3 cells were pulsed with 0.3 µM ethynyl uridine for 2h, then chased in media without 
ethynyl uridine while being treated with 500 µM palmitate or vehicle. Total RNA was collected, 
ethynyl uridine-containing RNA was labeled with click-biotin, and labeled RNAs collected with 
streptavidin:agarose beads. Labeled RNA was quantified by RTqPCR normalized to 18S rRNA, 
and quantity recovered at the end of the chase is reported relative to quantity labeled by pulse. 
Transcripts are grouped according to whether transcript abundance was found to be increased 
or decreased by RNAseq analysis. (Ddit3: DNA-damage inducible transcript 3; Ptx3: pentraxin 
related gene)  
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Table 3.4: Early changes in ribosome protected fragments during lipotoxicity 
NIH-3T3 cells were treated for 8h with 500 µM palmitate or vehicle. Ribosomes were stalled on 
transcripts with 100 µM cycloheximide. Ribosome protected fragments were generated by 
digesting unprotected RNA with RNase I, collected by centrifugation, and analyzed by RNA-seq. 
Table represents transcripts that were differentially abundant with >2-fold change among 
ribosome protected fragments. 
 
Table 3.4 Early changes in ribosome footprint abundance during lipotoxicity
Gene Symbol Description
P-value 
(adjusted)
Fold 
Change
Ppp1r15a Protein phosphatase 1, regulatory (inhibitor) subunit 15A 5.32E-22 10.6
Gadd45a Growth arrest and DNA-damage-inducible 45 alpha 6.88E-12 6.5
Hmox1 Heme oxygenase (decycling) 1 2.74E-20 5.4
Ddit3 DNA-damage inducible transcript 3 8.21E-11 4.7
Acot2 Acyl-CoA thioesterase 2 5.59E-07 4.3
Trib3 Tribbles homolog 3 (Drosophila) 4.71E-10 4.3
Slc3a2
Solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2 2.19E-18 3.9
Cth Cystathionase (cystathionine gamma-lyase) 3.09E-06 3.7
Chac1 ChaC, cation transport regulator 1 6.29E-07 3.7
Ndrg1 N-myc downstream regulated gene 1 1.77E-06 3.5
Slc6a9 Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 0.0000106 3.4
Atf4 Activating transcription factor 4 4.49E-11 3.4
Snhg12 Small nucleolar RNA host gene 12 0.0000587 3.3
Ddit4 DNA-damage-inducible transcript 4 0.0000736 3.3
Rgs16 Regulator of G-protein signaling 16 3.73E-07 3.2
Sqstm1 Sequestosome 1 2.21E-14 3.2
Psph Phosphoserine phosphatase 4.53E-07 3.1
Ptx3 Pentraxin related gene 0.0005051 3
Plk2 Polo-like kinase 2 2.58E-08 2.8
Herpud1
Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-
like domain member 1 0.0000732 2.7
Txnip Thioredoxin interacting protein 0.0026899 2.7
2410006H16Rik RIKEN cDNA 2410006H16 gene 0.0013976 2.7
Ets2 E26 avian leukemia oncogene 2, 3' domain 0.0000841 2.7
Cyb5r1 Cytochrome b5 reductase 1 4.43E-06 2.6
Lonp1 lon peptidase 1, mitochondrial 0.0000501 2.5
Nupr1 Nuclear protein transcription regulator 1 0.0005441 2.5
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 0.0032777 2.5
Emp2 Epithelial membrane protein 2 0.0006605 2.4
Fam110c Family with sequence similarity 110, member C 0.0095322 2.4
Cpt1a Carnitine palmitoyltransferase 1a, liver 0.0050433 2.3
Gpt2 Glutamic pyruvate transaminase (alanine aminotransferase) 2 0.0060359 2.3
Pck2 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.0004425 2.3
Steap1 Six transmembrane epithelial antigen of the prostate 1 0.0021258 2.3
Aldh1l2 Aldehyde dehydrogenase 1 family, member L2 0.0004077 2.3
Chka Choline kinase alpha 0.0060359 2.3
Nfkbia
Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, 
alpha 0.0196662 2.2
Slc7a5
Solute carrier family 7 (cationic amino acid transporter, y+ system),  member 
5 0.0005051 2.2
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mt-Cytb Mitochondrially encoded cytochrome b 0.0002565 2.2
Myc Myelocytomatosis oncogene 0.0001374 2.2
mt-Co3 Mitochondrially encoded cytochrome c oxidase III 0.0004077 2.2
Arid5b AT rich interactive domain 5B (MRF1-like) 0.0357954 2.1
mt-Nd4 Mitochondrially encoded NADH dehydrogenase 4 0.002218 2.1
Atf6 Activating transcription factor 6 0.0135638 2.1
Zc3hav1 Zinc finger CCCH type, antiviral 1 0.002263 2.1
Ero1l ERO1-like (S. cerevisiae) 0.0144764 2.1
Aldh18a1 Aldehyde dehydrogenase 18 family, member A1 0.0022899 2
Yars Tyrosyl-tRNA synthetase 0.0014051 2
Arhgef2 Rho/rac guanine nucleotide exchange factor (GEF) 2 0.0062115 2
mt-Nd5 Mitochondrially encoded NADH dehydrogenase 5 0.0062285 2
Dpf2 D4, zinc and double PHD fingers family 2 0.0197398 2
Ptgs2 Prostaglandin-endoperoxide synthase 2 0.0005188 2
Sars Seryl-aminoacyl-tRNA synthetase 0.0002565 2
Slc1a4 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 0.0175973 2
mt-Atp6 Mitochondrially encoded ATP synthase 6 0.0010882 2
Nop14 NOP14 nucleolar protein 0.0147009 2
Tgif1 TGFB-induced factor homeobox 1 0.0062115 2
Ptprs Protein tyrosine phosphatase, receptor type, S 0.0265368 -2
Col1a1 Collagen, type I, alpha 1 0.0001152 -2
Rps19 Ribosomal protein S19 0.0003289 -2
Rpph1 Ribonuclease P RNA component H1 0.0033912 -2
Dhcr24 24-dehydrocholesterol reductase 0.0002869 -2.1
Emilin2 Elastin microfibril interfacer 2 0.021616 -2.3
Fasn Fatty acid synthase 5.84E-07 -2.5
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Figure 3.3 Notable changes in translation efficiency 
Fold change in transcript and footprint abundance were calculated using DESeq2 for each gene 
upon palmitate treatment. Red dots represent genes for which there is more than a 2-fold 
difference in change in footprint abundance versus change in transcript abundance upon 
palmitate treatment, indicating possible translational regulation. 
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Table 3.5: Significant changes in translation efficiency 
Translation efficiency was calculated for each gene as ratio of transcript abundance versus 
footprint abundance. Translation efficiency ratio is translation efficiency for palmitate- versus 
translation efficiency for vehicle-treated cells. Table shows genes for which translation efficiency 
was significantly changed with palmitate treatment (p<0.05). 
 
 
 
 
Table 3.5 Significant Changes in Translation Efficiency
Gene Symbol Description
Translation 
Efficiency Ratio 
(Palm/Veh)
P-value 
(adjusted)
Rad21 RAD21 homolog (S. pombe) 45.0329 0.0146
Rac1 RAS-related C3 botulinum substrate 1 43.2587 0.0013
Fdft1 farnesyl diphosphate farnesyl transferase 1 33.0702 0.0017
Prmt1 protein arginine N-methyltransferase 1 30.9424 0.0024
Grn granulin 16.2327 0.0004
Cd44 CD44 antigen 11.8415 0.0112
Col1a2 collagen, type I, alpha 2 9.1776 0.0002
Psmc2
proteasome (prosome, macropain) 26S subunit, 
ATPase 2 8.7409 0.0146
Ncl nucleolin 4.7861 0.0000
Slc25a4
solute carrier family 25 (mitochondrial carrier, adenine 
nucleotide translocator), member 4 2.9591 0.0287
Sgk1 serum/glucocorticoid regulated kinase 1 0.4959 0.0004
Fkbp10 FK506 binding protein 10 0.4778 0.0004
Atic
5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase 0.4740 0.0407
Tmbim6 transmembrane BAX inhibitor motif containing 6 0.4465 0.0093
Cct5 chaperonin containing Tcp1, subunit 5 (epsilon) 0.4093 0.0010
Gm15662 predicted gene 15662 0.4054 0.0241
Cct7 chaperonin containing Tcp1, subunit 7 (eta) 0.3952 0.0378
Psmb4 proteasome (prosome, macropain) subunit, beta type 4 0.3909 0.0001
H2afx H2A histone family, member X 0.3681 0.0428
Cox5a cytochrome c oxidase subunit Va 0.3659 0.0248
mt-Tv mitochondrially encoded tRNA valine 0.3560 0.0065
Tcp1 t-complex protein 1 0.3431 0.0354
Fam198b family with sequence similarity 198, member B 0.2933 0.0156
Fpgs folylpolyglutamyl synthetase 0.2861 0.0492
Dcaf7 DDB1 and CUL4 associated factor 7 0.2827 0.0287
Srsf1 serine/arginine-rich splicing factor 1 0.2764 0.0372
Thoc5 THO complex 5 0.2519 0.0114
Eef1g eukaryotic translation elongation factor 1 gamma 0.2241 0.0009
Capns1 calpain, small subunit 1 0.2172 0.0000
Hist1h2ah histone cluster 1, H2ah 0.2093 0.0354
Kdelr2
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 2 0.1823 0.0018
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Sec24d Sec24 related gene family, member D (S. cerevisiae) 0.1810 0.0213
Sdpr serum deprivation response 0.1762 0.0159
Tpr translocated promoter region 0.1756 0.0083
Tnpo1 transportin 1 0.1676 0.0087
Tnc tenascin C 0.1624 0.0006
Psmd4
proteasome (prosome, macropain) 26S subunit, non-
ATPase, 4 0.1491 0.0293
Fubp1 far upstream element (FUSE) binding protein 1 0.1390 0.0240
Ybx1 Y box protein 1 0.1374 0.0152
Tnks1bp1 tankyrase 1 binding protein 1 0.1317 0.0000
Sep15 selenoprotein 0.1196 0.0065
Cfl1 cofilin 1, non-muscle 0.1195 0.0101
42069 membrane-associated ring finger (C3HC4) 6 0.1035 0.0354
Cav1 caveolin 1, caveolae protein 0.0906 0.0007
Eif3k eukaryotic translation initiation factor 3, subunit K 0.0862 0.0001
Atp6ap1
ATPase, H+ transporting, lysosomal accessory protein 
1 0.0824 0.0159
Cox6c cytochrome c oxidase subunit Vic 0.0747 0.0061
Actn1 actinin, alpha 1 0.0744 <0.0001
Slc4a1ap
solute carrier family 4 (anion exchanger), member 1, 
adaptor protein 0.0678 0.0373
Trp53 transformation related protein 53 0.0590 <0.0001
Ddost
dolichyl-di-phosphooligosaccharide-protein 
glycotransferase 0.0565 0.0009
Itgav integrin alpha V 0.0529 0.0006
Coa3 cytochrome C oxidase assembly factor 3 0.0486 0.0170
Arpp19 cAMP-regulated phosphoprotein 19 0.0478 0.0357
Nap1l4 nucleosome assembly protein 1-like 4 0.0465 0.0040
Txndc12
thioredoxin domain containing 12 (endoplasmic 
reticulum) 0.0450 0.0354
Rplp2 ribosomal protein, large P2 0.0442 0.0002
Tars threonyl-tRNA synthetase 0.0430 0.0000
Ddx23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 0.0360 0.0007
Rps13 ribosomal protein S13 0.0352 0.0492
Hist1h2bk histone cluster 1, H2bk 0.0311 0.0357
Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) 0.0275 <0.0001
Gnai3
guanine nucleotide binding protein (G protein), alpha 
inhibiting 3 0.0196 0.0140
Emd emerin 0.0103 0.0027
P4hb prolyl 4-hydroxylase, beta polypeptide 0.0061 0.0001
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Chapter 4 
Discussion 
In this study, we tested the hypothesis that the C/D box snoRNA U33, which accumulates in the 
cytosol during lipotoxicity and is required with the other Rpl13a snoRNAs for the lipotoxic 
response, forms non-canonical snoRNPs. We showed that in whole cell lysates U33 interacts 
with 28 proteins not previously described as snoRNP components. Additionally, we developed a 
method for the isolation of U33 complexes from subcellular fractions and identified a number of 
proteins whose interactions with U33 are dependent on fraction and treatment condition. We 
validated several of these interactions, including hnRNP A1 in whole cells and hnRNP U, 
KHSRP, G3bp1, and Caprin-1 in the cytosol of palmitate-treated cells. We hypothesized that 
U33 might direct the proteins in its cytosolic snoRNPs to act on cytosolic RNAs, particularly 
mRNAs, to  change mRNA abundance, half-life, or translation efficiency. Therefore, we 
performed RNA-seq and ribosome profiling on palmitate- and vehicle-treated cells. We found 
changes in transcript abundance and translation efficiency, as well as transcript stability, during 
lipotoxicity. Our findings that U33 forms non-canonical snoRNPs during lipotoxic stress and that 
gene expression during lipotoxicity is regulated at several levels are consistent with U33 
functioning in a non-canonical role in lipotoxicity. 
 
Although snoRNAs were initially thought to exclusively direct the canonical core snoRNP 
subunits to modify rRNA, more recent work has provided evidence for additional functions of 
snoRNAs. The first identified non-canonical role was for a subset of snoRNAs now termed 
scaRNAs. These small RNAs bind to canonical snoRNP subunits, but reside in Cajal bodies and 
direct modification of snRNAs.89,91 Other snoRNAs have been shown to form non-canonical 
snoRNPs that may relate to their unique functions. The brain-specific snordII-52 family of 
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snoRNAs interacts with a number of non-canonical proteins, including ELAVL1 and nucleolin, to 
direct the alternative splicing of the serotonin receptor 2C transcript.93,94 Human snoRNA ACA45 
and Giardia lamblia snoRNA GlsR17 are both processed to smaller microRNA species that 
function with Argonaute and modulate translation of Cdc2l6 and reporter constructs, 
respectively.95,96  
 
Our mass spectrometry results indicate that U33 interacts with a number of non-canonical 
snoRNP components, many of which were not previously identified as snoRNA binding proteins. 
Many of these interactions are dynamic, changing due to palmitate treatment or subcellular 
localization of U33. We hypothesized that U33 directs cytoplasmic complexes to modify 
cytoplasmic RNAs during lipotoxic stress. Therefore we focused our validation experiments on 
four proteins known to interact with mRNAs and found to associate with U33 in the cytoplasm 
after palmitate treatment, but not in the nucleus under basal conditions.  
 
hnRNP U is a multifunctional protein with RNA and DNA binding capabilities. Loss of hnRNP U 
leads to aberrant alternative splicing events and lethal defects in cardiac development.150 We 
selected this protein for validation because, in addition to its general RNA-binding capabilities, it 
has been shown to translocate to the cytoplasm of macrophages following lipopolysaccharide 
(LPS) treatment and to stabilize cytokine mRNAs.116 We found that hnRNP U was significantly 
increased in the cytosol of palmitate treated NIH-3T3 cells. Additionally, association of hnRNP U 
and U33 increased under these conditions. The transcripts stabilized by hnRNP U in LPS-
treated macrophages contain AU-rich elements (AREs) in their 3’-UTRs.116 hnRNP U interacts 
with these RNAs by binding to the AREs through its RGG motif; however, the mechanism of 
target identification is unknown and only a small subset of expressed ARE-containing mRNAs 
were affected by hnRNP U in this study.116 Intriguingly, our RNA-seq results indicate that during 
61 
 
lipotoxcity a significant number of differentially abundant transcripts also contain AREs. 
Metabolic labeling demonstrated changes in half-life that paralleled the changes in abundance 
measured by RNA-seq for all transcripts tested. Together, these results suggest a model 
whereby lipotoxicity induces interactions between U33 and hnRNP U in the cytoplasm, with U33 
directing those complexes to ARE-containing mRNAs, resulting in altered stability.  
 
Future studies will be required to determine whether U33 plays a role in stability of specific 
transcripts and whether there is a physical interaction involving U33, the mRNA, and hnRNP U. 
While such a mechanism might explain differential abundance for ARE-containing transcripts, 
there were also differentially expressed transcripts that did not contain identifiable AREs. It is 
possible that ARE-containing transcripts undergo changes in stability via one mechanism, while 
non-ARE-containing transcripts are regulated by a distinct mechanism. Furthermore, while most 
differentially abundant transcripts were increased by lipotoxicity, some were decreased; both 
groups included ARE-containing mRNAs. hnRNP U has primarily been associated with 
increasing ARE-containing transcript stability, leading to increased abundance of those 
transcripts.116 The decreases in transcript stability seen in our RNA-seq study may be due to 
factors besides hnRNP U, such as KHSRP. Alternatively, hnRNP U may mediate both up- and 
down-regulation of transcript stability, depending on cis-acting elements within the modulated 
RNA or the association of other proteins with the complex.  
 
KHSRP is another ARE-binding protein that regulates the stability of certain transcripts and that 
we have shown interacts with U33 in the cytoplasm of palmitate-treated cells. This protein binds 
AREs and recruits proteins involved in mRNA decay, leading to decreased stability.151 KHSRP 
tethers Parn, Ccr4, Dcp2, Xrn1, and Mtr3, as well as the exosome components Rrp4, Rrp46, 
and PM-Schl100, to its target transcripts.115 Although KHSRP appears capable of regulating 
62 
 
transcripts with different classes of ARE consensus sequences, it does not regulate all ARE-
containing transcripts.115 Additionally, KHSRP regulation appears to be cell-type specific. 
Further, the presence of additional cis-acting sequence elements within the mRNA can 
modulate the effect of KHSRP binding.115 The G-CSF mRNA contains what has been termed 
the stem-loop destabilizing element (SLDE) in its 3’-UTR and that is distinct from the ARE motif, 
while the c-fos transcript has a destabilizing sequence motif within the coding region.137,152  The 
stability of several other ARE-containing transcripts has been shown to be modulated by 
additional sequence elements in the 3’-UTR; while some of these also form stem-loops, these 
elements do not seem to form a single functional class.137,153 Furthermore, the molecular 
mechanisms by which these elements modulate mRNA stability are not well-understood, and it 
is possible that additional elements exist in other transcripts.    
 
Our mass spectrometry results indicate that KHSRP interacts with U33 in the cytosol during 
lipotoxic stress, but not in the nucleus under basal conditions. This suggests that KHSRP might 
contribute to the non-canonical role of U33 in lipotoxicity. However, pull-down/western blot and 
IP-qPCR validation experiments indicate that the interaction occurs in the cytosol with and 
without stress. One possibility is that U33 is always found in a complex with KHSRP in the 
cytosol, and that a modification to the complex or target(s) changes the ability of the complex to 
act on the target(s). That modification might be the addition or departure of another protein 
subunit to the complex, or a chemical modification such as phosphylation. Alternatively, KHSRP 
might not contribute directly to the role of U33 in lipotoxicity. Instead, KHSRP might tether U33 
in the cytosol.  
 
We also validated interactions between U33 and two stress granule (SG) components, G3bp1 
and Caprin-1. Stress granules are non-membrane bound cytoplasmic inclusions that are not 
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present under basal conditions, but that form in response to a variety of stresses.154 SGs have 
been observed in a variety of cell types in response to elevated temperature, oxidative stress, 
and exposure to UV light.155 The prevailing view is that these granules are storage sites for 
mRNAs in abortive translation complexes, which aggregate during periods of massive 
translational arrest.154,156-158 Some studies have implicated SGs as sites of mRNA degradation, 
although most mRNA turnover is thought to occur in P-bodies.157 SG nucleation is commonly 
precipitated by eukaryotic initiation factor (eIF) 2 phosphorylation, which inhibits translation 
initiation.154,159 Although there is debate in the literature, many studies indicate that mRNAs are 
triaged in SGs, with some transcripts being sorted to P-bodies for degradation, some being held 
in SGs for storage, and some transcripts with functions in the stress response being returned to 
the cytosol for resumption of translation.160 These studies are complicated by the dynamic 
nature of SGs, as well the overlap in protein constituents with P-bodies. Although the full 
complement of SG proteins is unclear and varies by stressor, G3bp1 has been shown to be a 
regulator of SG induction.161 
 
G3bp1 is an RNA binding protein with evidence of endonuclease activity.162 While it is required 
for SG formation in some experimental systems, other studies have indicated that SGs can form 
without this protein, albeit with smaller size and fewer interactions with P-bodies.161,163 G3bp1 
interacts directly with Caprin-1. Caprin-1 is required for normal progression through the G1-S 
phase of the cell cycle and also co-localizes with G3bp1 in stress granules.118,164 Through its 
carboxy-terminal region, Caprin-1 has been shown to bind select mRNAs, including c-myc and 
cyclin D2.118  Although its overexpression can drive eIF2 phosphorylation and global translation 
inhibition, Caprin-1 is not required for SG formation.118 While G3bp1 seems to play a role in 
regulating SG size and interactions with other RNA granules, the role of Caprin-1 in SG function 
remains undefined. 
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G3bp1 and Caprin-1 were found to associate with U33 in the cytosol of palmitate treated cells, 
but not in the nucleus of vehicle-treated cells. We chose to validate these interactions because 
we hypothesized that Rpl13a snoRNA accumulation in the cytosol results in changes in 
transcript abundance or translation efficiency that mediate lipotoxic cell death. One possible 
mechanism could involve sequestration of those transcripts in SGs, with U33 mediating 
selection of some mRNA targets. Validation experiments did show that U33 interacts with both 
proteins in the cytosol. However, palmitate treatment did not induce the appearance of SGs in 
NIH-3T3 cells. Treatment with the classical SG-inducer arsenite, which causes oxidative stress, 
resulted in robust aggregation of both Caprin-1 and G3bp1 in the cytoplasm of NIH-3T3 cells, 
indicating that these cells were competent for SG formation. One possible explanation is that 
these proteins do interact with transcripts that undergo translational arrest following palmitate 
treatment, but that lipotoxicity does not result in sufficiently “massive” translational arrest to 
induce SG aggregates that are visible by fluorescent microscopy. Both G3bp1 and Caprin-1 
have additional functions unrelated to SG formation. G3bp1 has been shown to cleave the ARE 
of c-myc in vitro. U33 could direct G3bp1 to degrade some mRNAs that are destabilized and 
less abundant during lipotoxicity, as shown in our RNA-seq study. Alternatively, U33 could direct 
G3bp1 and Caprin-1 to perform some yet to be described function(s) on the RNAs that are 
differentially abundant or differentially translated during lipotoxic stress. Similarly to results for 
KHSRP, U33 was found to interact with G3bp1 and Caprin-1 in the cytosol in both palmitate- 
and vehicle-treated cells. Again, this could indicate that additional factors mediate a switch from 
inactive to active complexes during lipotoxicity.  
 
For proteins shown to interact with U33 in the cytoplasm during lipotoxicity, future loss of 
function or knockdown studies would be useful to establish a role for each protein in lipotoxicity. 
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Loss of any one of these proteins might change the accumulation of U33 in the cytoplasm. This 
possibility is particularly intriguing for hnRNP U, whose accumulation in the cytosol mirrors that 
of U33; it is possible that the two traffic together. Alternatively, loss of one of these proteins 
might attenuate some or all of the changes in mRNA abundance, stability, or translation 
efficiency seen during lipotoxic stress. hnRNP U and KHSRP, given their published roles, are 
more likely to be linked to transcript stability and abundance. Due to the role of stress granules 
in both storing transcripts during translational arrest and sorting some of those transcripts to P-
bodies for degradation, G3bp1 and Caprin-1 could be involved in changing mRNA abundance, 
stability, and/or translation efficiency. 
 
While disruption of the Rpl13a locus, with subsequent loss of all four encoded snoRNAs, is 
protective against lipotoxicity, knockdown of individual snoRNAs by antisense oligo-mediated 
knockdown has no effect.42 This suggests that the functions of the snoRNAs in the lipotoxic 
response are either redundant or cooperative. Isolation of RNPs containing the remaining 
Rpl13a snoRNAs by antisense oligo-mediated pull-down, followed by mass spectrometry, will 
provide additional insights. The four snoRNAs might bind some of the same proteins, 
suggesting that they direct similar modifications. Alternatively, the snoRNAs might bind different 
proteins with related functions to facilitate cooperative action on a set of targets. Identification of 
the full set of proteins interacting with the Rpl13a snoRNAs will provide greater insight into their 
mechanism of action during lipotoxicity. 
 
We hypothesize that the Rpl13a snoRNAs direct chemical modifications of mRNA  
that alter stability and or translation efficiency. This could lead to changes in transcript 
abundance due to altered stability or changes in ribosome profiles due to altered translation 
efficiency. Indeed, RNA-seq identified over 200 transcripts with significant changes in 
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abundance. Additionally, 65 transcripts underwent significant and discordant changes in 
transcript abundance and ribosome protected footprint abundance during lipotoxicity, indicating 
a change in translation efficiency. In addition, metabolic labeling studies indicated that changes 
in transcript stability may have contributed to changes in transcript abundance. 
 
Intriguingly, the majority of differentially abundant transcripts during lipotoxic stress in fibroblasts 
showed an increase in abundance. As prolonged lipotoxic stress results in apoptosis, we 
expected most transcripts to decrease in abundance. A recent RNA-seq study of human islet 
preparations found that twice as many genes were downregulated as upregulated by palmitate 
treatment.119 That study was performed at 48 hours of treatment, a time point that resulted in a 
significant increase in propidium iodide (PI) positivity in treated cells. We chose a shorter time 
point during lipotoxic stress that preceded PI positivity, but was sufficient to observe cytoplasmic 
accumulation of the Rpl13a snoRNAs, because our goal was to investigate early effects of 
cytosolic snoRNA accumulation. The increased abundance of many transcripts might reflect 
activation of survival pathways during early lipotoxic stress. Significant enrichment of 
transcription factors among differentially expressed genes could function to regulate such 
adaptive pathways, a possibility that could be elucidated by additional experiments at later time 
points. Given that prolonged exposure to lipotoxic stress is lethal, we would expect that RNA-
seq performed at substantially later time points (e.g., 36-48 hours) would reveal a larger 
absolute number and relative amount of down regulated transcripts. 
 
Ribosome profiling, in combination with the RNA-seq study, identified 65 transcripts with 
significantly altered translation efficiency during lipotoxic stress. We developed a novel method 
to resolve the typically limited statistical power of small sample sizes, using a maximum a 
posteriori estimate for gene-specific sample variance and an exponential prior distribution of the 
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sample variance. These results indicate that gene expression during lipotoxicity is controlled not 
only at the level of transcription or mRNA abundance, but also at the level of translation. To our 
knowledge, this is the first study to define changes in the “translatome” of palmitate-treated 
cells. Additional experiments using snoRNA and/or snoRNP protein loss-of-function will be 
necessary to determine the contribution of Rpl13a snoRNAs and their associated proteins to 
changes in translation efficiency. In response to the oxidative stress induced by doxorubicin 
treatment, others in the Schaffer lab have observed that box C/D snoRNAs as a class 
accumulate in the cytosol with palmitate treatment.102 It is possible that changes in translation 
efficiency not due to Rpl13a snoRNAs are driven by other snoRNAs. Alternatively, changes in 
translation efficiency may occur via snoRNA-independent mechanisms. Although stress 
granules were not detected by immunofluorescence during lipotoxicity, some translation 
changes could be mediated by proteins that associate with stress granules. RNA-seq of 
transcripts co-precipitating with Caprin-1, G3bp1, or other stress granule components under 
basal and lipotoxic conditions could reveal whether these proteins bind transcripts shown to be 
translationally regulated.  
 
Identification of the cytoplasmic targets of the Rpl13a snoRNAs will provide insights into the 
function of the snoRNAs in lipotoxicity and add to our understanding of cellular functions carried 
out by these non-coding RNAs. The canonical snoRNA-target interaction occurs via duplex 
formation at an antisense element (ASE) immediately upstream of the D box.84 The antisense 
oligo (ASO) used to isolate U33 snoRNPs binds at this region. It is unknown whether U33 uses 
the canonical ASE for interactions in the cytosol, which would preclude isolation of U33-target 
complexes with this oligo. However, our RNase H assay identified a second region of U33, 
closer to the 5’ end, that is also available for binding under lysis conditions that preserve U33-
protein interactions. Isolation of U33 complexes with biotinylated oligos that bind either the ASE 
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or the upstream accessible region, followed by sequencing of co-precipitating RNAs might allow 
identification of U33 targets, as has recently been done for the H/ACA box snoRNA 
Snora73a.165 Additionally, comparison of the results with our RNA-seq and ribosome profiling 
results may provide insights into the effect of these interactions. We expect that this approach 
can be used to identify the targets of the Rpl13a snoRNAs, thereby providing additional insight 
into the mechanism of action of these noncoding RNAs in the cellular response to lipotoxic 
stress. 
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Chapter 5 
Materials and Methods 
 
Cell Culture 
NIH-3T3 cells (American Type Culture Collection) were cultured in Dulbecco’s Modified Eagle’s 
Medium containing 10% calf serum, 50 units/mL penicillin and streptomycin, and 2 mM L-
glutamine. For lipotoxicity experiments, 20 mM palmitate (Nu-Chek Prep) was freshly 
complexed to bovine serum albumin (BSA, Lampire) at 2:1 molar ratio as previously 
described,35 and added to cell culture media to achieve final palmitate concentration of 500 µM. 
Equivalent amount of BSA (vehicle) was added to control samples. Incubations in palmitate or 
vehicle supplemented media ranged from 8-12 h. 
 
RNase H Assay 
Protocol was based on previously published approach111 and modified as follows. Whole cell 
lysates were generated by sonication in TNEN (50 mM Tris pH 8, 150 mM NaCl, 0.1. mM 
EDTA, 0.05% NP-40) for 10 pulses of 10 seconds each, separated by 1 minute on ice. 
Sonication was performed with Branson Sonifier 250 with microtip attachment at setting 4, 80% 
duty cycle, corresponding to ~25 watts.  Sonicate was subsequently centrifuged at 7,000xg at 
4oC to pellet unbroken cells and nuclei. Supernatant was collected for RNAse H analysis.  
Reactions contained equal volumes sonicate and 2X buffer (100 mM KCl, 10 mM MgCl2, 2 mM 
DTT, 10% glycerol), 0.5 µL RNase H (Life Technologies), and 1 µL DNA oligo or water. 
Reactions were incubated in a thermal cycler at 37oC for 15 minutes, then 30oC for 20 minutes. 
Reactions were stopped with 9X volume of stop solution (0.1% SDS, 5 mM EDTA). RNA was 
isolated by phenol:chloroform extraction and quantified by RTqPCR. 
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RNA Reverse Transcription and Quantitative PCR 
RNA isolated by phenol:chloroform extraction or with TRIzol or TRIzol LS (Life Technologies) 
per manufacturer’s instructions was reverse transcribed using Superscript III First Strand 
Synthesis System (Life Technologies) per manufacturer’s protocol. cDNA synthesis was primed 
using random hexamers or oligo dT for rRNA and mRNA targets, or stem-loop or gene-specific 
primers for snoRNAs, tRNAs, and 7SK. cDNA was amplified through 40 PCR cycles with Power 
SYBR Green PCR Master Mix (Applied Biosystems) and 100 nM each forward and reverse 
primers. Relative quantification of gene expression was performed using the comparative 
threshold method. Relative quantification of RNA co-precipitating with antisense oligo or protein 
immunoprecipitation was performed as 2
DCT. 
 
SnoRNP Isolation 
Whole cell lysates were generated by sonication in TNEN for 5 pulses of 5 seconds each, 
separated by 1 minute on ice. Sonication was performed with Branson Sonifier 250 with microtip 
attachment at setting 4, 80% duty cycle, corresponding to ~25 watts. Sonicate was centrifuged 
at 7,000xg at 4oC and supernatant was collected. For isolation of cytosol and post-cytosol, cells 
were disrupted in TNEN by 10 strokes with Dounce homogenizer, then centrifuged at 20,000xg 
for 30 minutes at 4oC. U6 RNA and protein markers (hsp90, histone H3, and nucleophosmin) 
were used to validate subcellular fractionation by RTqPCR and western blot, respectively. 
Supernatant was collected for cytosolic snoRNP isolation. Pellet was rinsed three times with 
cold PBS then sonicated in TNEN as above. 250 µL lysate was incubated with 1 nanomole dual-
biotinylated oligo (IDT) for 1.5 hours at 4oC with end-over-end rotation. 30 µL packed bead 
volume of High-Capacity Streptavidin beads (Pierce) were incubated with lysate for 30 minutes 
at 28oC. Beads were washed twice with 500 µL and three times with 1 mL TNEN. 90% of beads 
were pelleted and protein collected by boiling in Laemmli sample buffer. RNA was isolated from 
remaining 10% of beads with TRIzol-LS. 
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Mass Spectrometry 
Protein from three pull-down experiments was pooled. Samples were diluted in 400 µL buffer 
UA (8 M urea, 100 mM Tris pH 8.5) and concentrated with Amicon Ultra 10 kD filter two times. 
100 µL of 50 mM iodoacetamide in buffer UA was added to each sample and incubated five 
minutes in the dark. Samples were diluted in 300 µL buffer UB (8 M urea, 100 mM Tris pH 8) 
and concentrated with Amicon Ultra 10 kD filter three times. Buffer-exchanged samples were 
stored at -80oC until mass spectrometry analysis. Proteins were in-solution digested with trypsin 
after reduction with dithiothreitol and alkylation with iodoacetamide. Samples were desalted on a 
C18 ziptip prior to LC/MS analysis, which was acquired on an AB SCIEX 5600 nano-LC/MS 
system in data-dependent acquisition mode. Peptides were identified using MASCOT by 
MS/MS database searching against the UniProt mouse reference database with fixed 
carbamidomethyl and variable methionine oxidation modifications. Mascot results were loaded 
into Scaffold for protein grouping after filtering for peptides with a 1% FDR and requiring 2 
peptides detected per protein. Total spectral counts were used for spectral counting. Proteins 
with a minimum of 2 (whole cell) or 5 (subcellular compartment) peptides and a 2:1 ratio of 
peptides in the antisense versus sense pull-down were considered enriched. Whole cell pull-
downs were performed in duplicate. LC/MS data acquisition and protein identification were 
performed in collaboration with Dr. Jason Held. 
 
Western blot 
Proteins from cell lysates or pull-downs were separated by gel electrophoresis on 10% sodium 
dodecyl sulfate-polyacrylamide gel and transferred to nitrocellulose membrane (Whatman) by 
semi-dry method. Membranes were blocked with Relia-blot Blocking reagent (Bethyl) or 1% 
BSA (Sigma) in TBST overnight and probed with primary antibodies to fibrillarin (1:1000, 
Bethyl), Nop56 (1:3000, Bethyl), hnRNP A1 (1:3000, Abcam), hsp90 (1:750, Enzo/Stressgen), 
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nucleophosmin (1:1000, Abcam), histone H3 (1:5000, Abcam), hnRNP U (1:1000, Abcam), 
KHSRP (1:1500, Bethyl), Caprin-1 (1:1000, Protein Tech/Fisher), or G3bp1 (1:750, Abcam) for 
2 hours at room temperature. Membranes were incubated with appropriate secondary 
antibodies (1:10,000, Jackson ImmunoResearch Laboratories) conjugated to horseradish 
peroxidase (HRP) for 1 hour at room temperature, then proteins were visualized with Western 
Lightning-Plus chemiluminescence substrate (PerkinElmer Life Sciences) on a BioRad 
ChemiDoc XRS+ imaging system.  
 
Protein Visualization 
Proteins from pull-downs were separated by gel electrophoresis on 10% sodium dodecyl 
sulfate-polyacrylamide gel. Gels were fixed for 2 hours in 7% acetic acid/10% methanol, washed 
three times in 10% methanol for 20 minutes each, stained for 90 minutes with SYPRO Ruby 
(Life Technologies), and washed once with 10% methanol for 20 minutes. Proteins were 
visualized on a BioRad ChemiDox XRS+ imaging system. 
 
Immunoprecipitation 
Proteins were immunoprecipitated from cytoplasmic lysates generated by Dounce 
homogenization in TNEN as above. Lysates were precleared for 15 minutes with protein 
A:agarose (Roche), incubated with 1-2 µg of same antibodies used for western blot for 2 hours, 
then incubated with 1/10th volume protein A:agarose for 45 minutes, at 4oC with rotating. Beads 
were washed three times with 1 mL cold TNEN and once with 1 mL cold PBS. RNA was 
collected from 40% of beads with TRIzol. Protein was collected from remainder of beads with 
Laemmli sample buffer. 
 
RNA Stability Analysis 
Cells were pulsed with 0.3 µM ethynyl uridine for 2 hours at 37oC. Cells were then treated with 
palmitate:BSA or vehicle as above during chase in media lacking ethynyl uridine. Total RNA 
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was collected with TRIzol immediately after ethynyl uridine pulse or after chase. RNA was 
biotin-labeled via click reaction, and labeled RNA was isolated with streptavidin magnetic beads 
using Click-It Nascent RNA Capture Kit (Life Technologies) per manufacturer’s instructions. 
Labeled RNA was quantified by RTqPCR and normalized to 18S rRNA. 
 
RNA-seq and RPF-seq 
Cells were treated with palmitate or vehicle for 8h as above. For RNA-seq, total RNA was 
isolated with TRIzol. Ribosomal RNA was removed by Ribo-Zero as part of cDNA library 
preparation by the Genome Technology Access Center (GTAC) at Washington University 
School of Medicine. For ribosome footprint (RPF)-seq, samples were prepared as previously 
described.139 Briefly, cells were lysed in buffer containing 1% Triton X-100 and 100 µM 
cycloheximide to stall ribosomes. Unprotected RNA was digested with RNase I (Life 
Technologies). Ribosomes and protected RNA were pelleted. RNA was extracted from pellets 
with miR-Vana RNA Isolation Kit (Life Technologies). 3’-linker was ligated to footprints and RNA 
was reverse transcribed. Ribosomal cDNA was removed by subtractive hybridization with 
biotinylated antisense oligos directed against 5.8S, 18S, and 28S and captured with magnetic 
streptavidin beads. PCR amplified libraries were sequenced by GTAC. Raw reads were pre-
processed with the FASTX toolkit to trim low quality regions or linkers and ribosomal RNA 
sequences removed by alignment with Bowtie2 to the Silva mouse rRNA database.166-168 
Processed reads were then aligned to the Ensembl R73 mouse genome using Tophat.169,170 
Individual reads were mapped to genes using htseq-count to produce counts of total aligned 
reads for each gene in each sample.171 DESeq2 analysis was used to identify transcripts 
differentially represented in palmitate- and vehicle-treated samples based on differences in 
normalized gene counts.172 Computational analysis was performed in collaboration with Dr. Brett 
Olsen and Dr. Daniel Ory. 
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Gene Ontology (GO) Analysis 
Gene lists were generated containing all significantly up-regulated genes, all significantly down-
regulated genes, and all significantly differentially expressed genes identified by mRNA-seq as 
analyzed by DESeq2. GO term enrichment was assessed for each gene list using the Database 
for Annotation, Visualization, and Integrated Discovery (DAVID) 6.7.124,125 All gene lists were 
compared to a custom background gene list (n=18,852) of genes detected by mRNA-seq. 
 
Gene Set Enrichment Analysis (GSEA) 
One custom gene set was created for each of seven AU-rich element consensus sequences, 
using lists downloaded from ARE 1.0 (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi).133 The 
expression dataset contained normalized mRNA-seq data as fragments per kilobase of 
transcript per million mapped reads (FPKM) from two palmitate-treated and two vehicle-treated 
samples. GSEA was run with 10,000 gene-set permutations to generate a Kolmorgovor-
Smirnov type statistic measuring enrichment of gene sets up-regulated by palmitate treatment 
relative to vehicle.135,136 
 
Calculating Translational Efficiency 
We modeled the read counts for each gene as a discrete random variable drawn from a distinct 
negative binomial distribution for each sample and gene. The mean parameters were modeled 
as the product of a sample-specific size-factor and a condition and method-dependent gene-
specific expression factor and estimated as described elsewhere.142 Dispersion parameters 
were estimated using a maximum a posteriori approach for each condition and method (RNA-
seq or RPF-seq) using an adjusted fixed-point method173 with an exponential prior 
distribution.174 Translation efficiency was estimated for each gene and condition as the bias-
corrected ratio of expression factors for footprint to RNA-seq data. P-values testing against the 
null hypothesis of no difference in translation efficiency between control and palmitate samples 
were estimated as the tail probabilities of the joint probability distribution over count sums for 
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each method and condition using a pooled translation efficiency parameter and adjusted for 
multiple hypothesis testing using a Benjamini-Hochberg correction with 5% false discovery 
rate.175 Translation efficiency analysis was performed in collaboration with Dr. Brett Olsen and 
Dr. Daniel Ory. 
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Table 5.1 Primer and oligonucleotide sequences 
 
Table 5.1 Primer and oligonucleotide sequences
Application Primer/Oligo Sequence
RNase H Assay U33 ASO 1-15 5’- TCTCATCACAAGCTG-3’
U33 ASO 15-29 5’- ATGAGTGGGAGATGT-3’
U33 ASO 29-43 5’-CGAGCAACTCGAACA-3’
U33 ASO 43-57 5’- AGTCATCTCATAGTC-3’
U33 ASO 57-71 5’-GGTAGTGCATGTAGA-3’
U33 ASO 69-83 5’-ACAGCCTCAGATGGT-3’
Reverse 
Transcription mU17b SLRT1 5′-GCGTGGTCCCGACCACCACAGCCGCCACGA CCACGCTTTTGT-3ʹ
mU20 SLRT1 5'-GCGTGGTCCCGACCACCACAGCCGCCACGA CCACGCCTGGAT-3'
mU33_SLRT1 5'-GCGTGGTCCCGACCACCACAGCCGCCACGAC CACGCACAGCCTC-3’
mU34_SLRT1 5'-GCGTGGTCCCGACCACCACAGCCGCCACGA CCACGCAGCGTCTC-3’
mU35a_SLRT1 5'-GCGTGGTCCCGACCACCACAGCCGCCACGA CCACGCTCCTGGCA-3’
Glu tRNA SLRT2 5'-CTCAGCGGCTGTCGTGGACTGGGTGCTGCC GCTGAGTGGTTCCCTGA-3’
U6 RT 5’-AAT ATG GAA CGC TTC ACG AAT-3’
qPCR m364B F1 5’-ATC CCT GAC GCA CCG CCG TGA-3’
m364B R1 5’-TGC ATC TGC TTG GAG CCC ACG TT-3’
18S F 5'-ACG GAC AGG ATT GAC AGA TTG-3'
18S R 5'-ATG CAC CAC CAC CCA CG-3'
Stem Loop Universal R1 5'-TCC CGA CCA CCA CAG CC-3'
mU20 F 5'-TGGATATGATGACTGATTACCTG-3'
mU32a_F1 5’-GAGTCCATGATCAGCAACACTCACC-3’
mU33_F1 5’-AGCTTGTGATGAGACATCTCCCACT-3’
mU34_F1 5’-CGTCTGTGATGTTCTGCTATTACCTACATTGTT-3’
mU35a_F1 5'-GGCACATGATGTTCTTATTCTCACGATGGT-3'
U6 F1 5'-GCT TCG GCA GCA CAT ATA CTA-3'
U6 R1 5'-CGAATTTGCGTGTCATCCTTG-3'
mU17b F 5ʹ- AACGGGAGCTTAGGGCATT-3ʹ
snoRNP 
Isolation mU33 ASO dual biotin
5'-/5BiosG/mUmGmGmUmAmGmUmGmCmAm 
UmGmUmAmGmAmGmUmCmA/3Bio/-3'
mU33 sense dual biotin 5'-/5BiosG/mUmGmAmCmUmCmUmAmCmAmUm GmCmAmCmUmAmCmCmA/3Bio/-3'
ribosomal 
cDNA 
subtractive 
hybridization
SubHyb 1 18S 5'-/5BioTEG/GGGGGGATGCGTGCATTTATCAGATCA-3'
SubHyb 2 18S 5'-/5BioTEG/TTGGTGACTCTAGATAACCTCGGGCCGATCGCACG-3'
SubHyb 3 18S 5'-/5BioTEG/GAGCCGCCTGGATACCGCAGCTAGGAATAA TGGAAT-3'
SubHyb 4 28S 5'-/5BioTEG/TCGTGGGGGGCCCAAGTCCTTCTGATCGAGG CCC-3'
SubHyb 5 28S 5'-/5BioTEG/GCTTTCGCCGAATCCCGGGGCCGAGGAAG CCA-3'
SubHyb 6 28S 5'-/5BioTEG/GGGGCCGGGCCGCCCCTCCCACGGCGCG-3'
mU32a_SLRT1 5’-GCGTGGTCCCGACCACCACAGCCGCCACGAC CACGCCGAGTCTC-3’
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SubHyb 8 28S 5'-/5BioTEG/CCCAGTGCGCCCCGGGCGTCGTCGCGCCG TCGGGTCCCGGG-3'
SubHyb 9 28S 5'-/5BioTEG/TCCGCCGAGGGCGCACCACCGGCCCGTCTC GCC-3'
SubHyb 10 28S 5'-/5BioTEG/AGGGGCTCTCGCTTCTGGCGCCAAGCGT-3'
SubHyb 11 28S 5'-/5BioTEG/GAGCCTCGGTTGGCCCCGGATAGCCGGGT CCCCGT-3'
SubHyb 13 28S 5'-/5BioTEG/TCGCTGCGATCTATTGAAAGTCAGCCCTCGAC ACA-3'
SubHyb 14 5.8S 5'-/5BioTEG/TCCTCCCGGGGCTACGCCTGTCTGAGCGTC GCT-3'
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